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MULTIWALL CARBON NANOTUBES ALTER THE THERMAL PROFILE AND 
ANTIBIOTIC ELUTION OF ORTHOPAEDIC BONE CEMENT 
 
 
  Multiwall carbon nanotubes (MWNTs) have extraordinary mechanical and 
thermal transport properties.  They significantly improve the static and dynamic 
mechanical properties of acrylic orthopaedic bone cement when added to the dry cement 
polymer powder.  Understanding the role MWNTs play on bone cement polymerization 
temperatures will lead to improved mechanical integrity of the cement-bone interface in 
joint arthroplasties.  It was determined through thermal testing that MWNTs increased 
the polymerization time of the methylmethacrylate by 45-460% and decreased the peak 
exothermic temperature of bone cement with and without antibiotics.  The flow of heat 
produced during polymerizing cement was reduced 25-85% with the addition of MWNTs 
to the cement powder.  This decreases the probability of thermal necrosis and “hot” spots 
caused by high exothermic polymerization temperatures that can destroy the bone 
adjacent to the cement.  These high temperatures also affect the potency and range of 
antibiotics used in arthroplasty.  Isothermal and elution studies determined that MWNTs 
altered the heat flow and amount of antibiotic release from bone cement during 
polymerization.  Antibiotic elution from bone cement containing MWNTs could match 
the elution seen in pure cement.  The alteration of the flow of heat from bone cement 
leads to new options for heat-labile antibiotics in total joint arthroplasty.   
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Chapter 1 - Background 
 
Section 1.1   A rthroplasty  
 
Section 1.1.1   History and Functions 
 
The idea of knee replacement or resurfacing was first conceptualized in the late 1860s 
[1].  Modern arthroplasties have been performed around the world for over sixty years.  
This procedure can be performed as a result of trauma or injury, osteo-arthritis, 
rheumatoid arthritis, congenital disease, or other miscellaneous causes.  Total hip 
replacement was first successfully performed in the United Kingdom in 1962, and 
approved for use in the United States in 1969 [2, 3].  Acrylic bone cement is used in the 
fixation of artificial joints and the anchoring of metallic prostheses to bone.   
 
Otto Röhm was one of the first to discuss the polymerization of methacrylates more than 
70 years ago [4].  The manufacture of polymethacrylates commercially led to a rapid 
development of new polymers.  The polymer polymethylmethacrylate has been used in 
medical applications since the late 1930s [5].  In 1936, heat-curable dough was patented 
by the company Kulzer.  The dough was made by mixing polymethylmethacrylate 
(PMMA) powder with liquid methylmethacrylate (MMA) and a heat-sensitive initiator.  
In 1943, Kulzer and the company, Deguss, developed the first cold-curing cement [4].  
This type of cement does not require additional heating to cure.  The cement materials 
were used to fill defects in the skeleton and to produce cranial plates.  Sir John Charnley 
first succeeded in anchoring femoral head prostheses in the femur with self-curing 
cement in 1958 [6].  Prosthetic devices with polymethylmethacrylate (PMMA) permitted 
better range of motion while preserving the stability of the joint.  Knee designs improved 
rapidly during the 1970s and 1980s as a result of the more reliable fixation that cement 




Bone cement fills the space between the prosthesis and bone.  It acts as an elastic buffer 
and a load transfer system that moves the load from the implanted prosthesis to the host 
bone.  This distribution of stresses is important for the long-term stability of the implant.  
Cement fracture can result if the external stresses are greater than the cement’s ability to 
transfer the load [4].  Bone cement is also commonly used in resurfacing arthroplasty in 
addition to primary and revision total joint arthroplasty.  The success or failure of a 
replacement joint is determined by the success of the bone cement fixation. 
 
Section 1.1.2   Current Clinical Data 
 
Joint replacement surgeries, most notably hip and knee, are some of the most frequently 
performed surgical procedures in the world.  Total hip and knee joint replacements were 
the most common major orthopaedic surgical procedures in 2006, with approximately 
one million performed annually world-wide [7].    About 160,000 of those total hip and 
knee replacement procedures were carried out in England and Wales and about 500,000 
in the United States [8, 9].  Total joint replacement is the most successful method of 
treating end-stage arthritis.  It improves the quality of life and functional capability of 
arthritic disease patients.  In Sweden, over 95% of hip arthroplasties and over 98% of 
knee arthroplasties use bone cement for the fixation of at least one component [7].  In the 
United Kingdom, bone cement is used to secure the metallic prosthesis to the bone in 
more than 90% of total joint replacements [7, 10].  In the United States, over the period 
1979-2000, approximately 77% of primary total knee joint replacements were cemented 
[11].  The in vivo longevity of cemented total joint replacements is very good.  The 10-
year survival rate of cemented total hip joint replacements (THJRs) being between 94-
96% [11].   
 
In 2003, 202,500 primary total hip arthroplasties and 402,100 primary total knee 
arthroplasties were performed in the US according to Nationwide Inpatient Sample (NIS) 
and National Hospital Discharge Survey (NHDS) data [12].  The number of total hip 
revision arthroplasties that year was 36,000 and the number of total knee revisions was 
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32,700.  Over the next two decades there is going to be a massive demand for primary 
and revisions surgeries.  Overall, revision rates in the first three years after a hip or knee 
replacement in England since April of 2003 were low.  Only about one in 75 patients 
needed a prosthesis revision within three years. The cemented hip and cemented knee 
prostheses had the lowest revision rates [13].   
 
A methodology to project the prevalence of arthroplastic surgery in future years was 
developed [12].  Using NIS data, the demand for primary total hip arthroplasty was 
estimated to increase by 174% between 2005 and 2030.  If the number of total knee 
arthroplasties performed yearly continues at the current rate, the demand for primary total 
knee arthroplasty is predicted to increase by 673% by 2030.  The total number of revision 
arthroplasty procedures performed in 2005 is expected to double by 2026 for revision hip 
arthroplasty and by 2015 for revision knee arthroplasty.  The total number of total hip 
arthroplasty revisions was estimated to increase by 137% by 2030 and the total number of 
total knee arthroplasty revisions was estimated to increase by 601% [12].  They projected 
a massive increase in demand for primary and revision total joint procedures over the 
next two decades that will need to be addressed by increasing economic resources, 
operative efficiency, number of surgeons, and implant longevity.  The results are based 
on historical data which may not be an accurate prediction of the future depending on the 
quality of the available data, the sample size, and improvements to the implant 
technology or surgical procedure. 
 
If the number of infection cases is increasing along with the number of procedures being 
completed, infection during arthroplasty is becoming a growing problem.  As the number 
of infection cases increase, the number of revisions that must be completed also 
increases.  Deep infection after total knee arthroplasty (TKA) or total hip arthroplasty 
(THA) frequently results in the need for multiple surgical interventions, the need for 
extended duration parenteral antibiotics, and possible compromised function of 
subsequent revision TKA or THA [14].  The health care costs of reconstructing 
previously infected TKAs and THAs have been estimated to be approximately 5 times 
4 
 
that of a primary TKA or THA [15].  Deep infection represents a tremendous economic 
burden [16].   
 
The Swedish Knee Registry reported that deep infection occurs in 1.7% of total knee 
arthroplasty patients with osteoarthritis and 4.4% of patients with rheumatoid arthritis 
[17].  Other sources report infection rates of 1-3% in patients undergoing knee 
arthroplasty for osteoarthritis [18] and up to 8% for patients having a knee replacement 
for rheumatoid arthritis [19].  The overall incidence of deep infection has also 
substantially increased between 1990 and 2003 for both total hip arthroplasty and total 
knee arthroplasty [20].  In 2003, approximately 1.2% of the total hip and total knee 
arthroplasties performed in the United States were associated with deep infection.  The 
risk of infection after revision arthroplasty is higher than after primary arthroplasty [21].  
The number of infections seen in the United States currently reaches as high as 8,000 to 
10,000 per year [22].  Because of the enormous number of surgical procedures completed 
each year, even with low infection rates, the impact on morbidity, mortality, and medical 
costs is huge [23].  Deep infections are extremely costly to treat and cause the patient 
pain and discomfort.  The annual hospital charges for primary total hip arthroplasty were 
estimated at $5.1 billion and estimated at $9.1 billion for primary total knee arthroplasty 
in 2005 [24].  Hospital charges for revision total hip arthroplasty and revision total knee 
arthroplasty were estimated in 2005 as $1.3 billion and $0.91 billion, respectively [16].   
 
The incidence of deep infection after primary TKA is rising and has been projected to 
reach 6.8% by 2030 [25].  This infection percentage may be increasing as a result of 
patient or infectious organism resistance to the commonly used antibiotics.  Also, the 
infectious organisms may start working synergistically to increase the presence of 
infections.  It was also projected that hip arthroplasty revisions done because of infection 
will increase from 8.4% in 2005 to 47.5% in 2030 [25].  Similarly, knee arthroplasty 
revisions as a result of infection were projected to increase from 16.8% in 2005 to 65.5% 
in 2030 [25].  The incidence of deep infection was projected to exceed 50% after 2030 
for total hip arthroplasty and by 2022 for total knee arthroplasty [25].  The actual 
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percentages of total surgery infection numbers were estimated to increase from 1.4% in 
2005 to 6.5% for total hip arthroplasty [25].  For total knee arthroplasty, the total 
infection burden is projected to increase from 1.4% in 2005 to 6.8% in 2030 [25].  
Annual hospital charges were estimated to increase between 2005 and 2015 by 340% to 
$17.4 billion for primary total hip arthroplasty and by 450% to $40.8 billion for primary 
total knee arthroplasty [25].  Hospital charges for revision total hip arthroplasty and 
revision total knee arthroplasty were projected to increase by 290% to $3.8 billion and by 
450% to $4.1 billion by 2015 [25].  This provides strong motivation for clinical and 
technological innovators to develop more effective and timely countermeasures for 
infection at the site of a joint arthroplasty.   
 
Section 1.2   Bone Cement 
 
Section 1.2.1   Composition and Structure 
 
The biomaterial used in most arthroplasties for fixing components to bone cement.  In 
2008, there were over 30 commercially available plain acrylic bone cement brands 
approved by relevant regulatory authorities [11].  Each of the commercial bone cement 
manufacturers makes products with slight differences.  The basic composition of the 
products is the same, typically called the two-component bone cement system.  The 
manufacturers supply polymer powder in sterile packaging and monomer liquid in an 
ampule.  MMA is the main ingredient of the monomer, 97-99 wt% [11].  It is a clear, 
colorless, intensely smelling, flammable liquid.  MMA is an ester of methacrylic acid 
with a polymerizable double bond.  The MMA also contains N,N-dimethyl-para-toluidine 
(DMPT) (0.4-2.8 wt%), a tertiary amine that acts as an activator [11] and enables cold 
curing of the polymer, eliminating the need to preheat the material prior to 
polymerization [5].  The liquid is also stabilized with small amounts of hydroquinone 
(15-75 ppm) to guarantee shelf-life and to prevent polymerization during storage of the 
product [4, 11].  Even small amounts of the monomer liquid are detectable by smell, 
because the odor threshold is only approximately 0.2 ppm [1].   
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The polymer powder is comprised of beads of pre-polymerized PMMA-based polymer, 
or MMA copolymers (83-99 wt%) and benzoyl peroxide (BPO) (0.75-2.6 wt%).  The 
BPO is the polymerization reaction initiator and is required to initiate curing of the 
cement.  It reacts with the DMPT to create free radicals that break the carbon double 
bonds and start the polymerization process [5].  The powder also contains a radiopacifier.  
The two most commonly added ones include barium sulfate (BaSO4) or zirconium 
dioxide (ZrO2), (9-15 wt%).  The radiopacifiers are contrasting agents that confer 
radiopacity and aid in the radiographic assessment of implants.  A few manufacturers also 
add chlorophyllin to their cements to tint the cement to a green color.  This allows for 
better distinction from body tissues during surgery [5].  Additives like these, plus 
antibiotics, do not take part in the curing process or free-radical polymerization.  There 
are considerable differences between the powder components of different 
commercialized cements that account for the variations in properties of cements, 
therefore influencing their performance and the success of the arthroplasty.  The 
mechanical and elution properties of the different cements vary as a result of their 
different components or differences in cement preparation [1].   
 
Section 1.2.2   Polymerization Process 
 
There are two processes that occur when the two-component system is combined.  First, 
the polymer powder takes up the monomer liquid, called the “wetting” stage.  This 
mixture quickly forms a viscous fluid or dough, called the “dough” stage.  During this 
phase, the monomer and polymer powders experience swelling and dissolution processes 
that are important for the characterization of bone cement.  Second, a chemical process is 
initiated.  The initiator, BPO, from the polymer powder and the DMPT, from the liquid, 
interact to produce free radicals in what is known as the “initiation reaction”.  These 
radicals are able to start the polymerization of MMA by adding to the polymerizable 
double-bond of the monomer molecule.  A polymer chain begins to build up by adding 
monomer molecules [26].  Polymer chains from the PMMA become available for free 
radical polymerization and entanglements of these chains with newly formed chains leads 
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to a connection between the newly formed PMMA with what was already present [5].  
The number of radicals generated is high, so many rapidly growing polymer chains are 
formed.  This leads to the fast conversion of MMA to PMMA.  The polymerization 
process takes only a few minutes.  Radical polymerization of the MMA generally does 
not proceed to completion.  The mobility of remaining monomer molecules is hindered at 
high conversion rates.  There is approximately 2-6% residual monomer directly after 
curing [27].  Over the few weeks after curing, the amount of monomer remaining 
unpolymerized decreases.   
 
The dough phase is important because is offers the possibility of moulding and being 
used to support a prosthesis, while allowing its insertion.  The doughy phase is also 
susceptible to outside factors.  The temperature of the monomer or polymer, ambient 
room temperature, and humidity impacts polymerization.  Lower temperatures inhibit the 
monomer-polymer reaction and less monomer is allowed to evaporate.  This leads to a 
higher concentration of free monomer, a prolongation of handling time, and a longer 
setup time from the liquid to the doughy state [1].   
 
The polymerization of acrylic bone cement is exothermic, with the maximum 
polymerization temperature being high enough that thermal necrosis of the peri-prosthetic 
tissue may occur [11].  Cement also plays a role in chemical necrosis of the bone as a 
result of the release of unreacted monomer liquid before polymerization of the cement 
[28].  The high polymerization temperature was one of the believed reasons for aseptic 
loosening of prostheses.  The high exothermic termperature of bone cement has also been 
identified as playing a role in impaired local blood circulation and the formation of a 
membrane at the cement-bone interface.  There is 57kJ of heat formed per mole of MMA 
(molar mass of MMA = 100 g) [26].  This heat formation results in an increase in the 
temperature of the curing bone cement.  The maximum temperature can be influenced by 
the chemical composition of the cement, by the powder to liquid ratio, and by the 
radiopacifier.  The maximum in vitro temperature according to ISO and ASTM standards 
is approximately 140-176oF.  This maximum temperature is only held for a very short 
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time, and when measured in vivo it is lower.  Clinical trials showed a maximum 
temperature of approximately 104-115oF at the interface of bone and cement [4].  The 
lower in vivo temperatures are because of the thin layer of the bone cement used and heat 
dissipation to the prosthesis and to surrounding tissue [26].   
 
 Section 1.2.3   Properties 
 
Each manufacturer’s cement has a unique set of material properties that the surgeon must 
understand.  Some of these differences include the viscosity of the initial liquid phase, the 
length of time for the liquid phase, the length of time for the doughy phase, and the time 
from doughy state to the solid state.  Surgeons may prefer one characteristic or 
manufacturer according to the requirements of their arthroplasty technique.  Most 
surgeons prefer one type of cement and then make adjustments as necessary for each 
surgery type [1].  There have been many types of cement and multiple manufacturers.  
These products have also been sold and passed from one manufacturer to another over 
time.  Some of the major manufacturers of bone cement include Biomet (Warsaw, 
Indiana, US), Zimmer (Warsaw, Indiana, US), Smith & Nephew (Memphis, Tennessee, 
US), Stryker (Mahwah, New Jersey, US), and Depuy (Warsaw, Indiana, US).  Their 
common current bone cement products include Refobacin, Palacos, VersaBond, Simplex, 
and CMW, respectively (Table 1).   
 
There are four different handling phases.  The first is the mixing phase (up to 1 minute).  
It is the period where the powder is thoroughly mixed into the liquid.  The second phase 
is the waiting phase (up to several minutes) and is the period to reach the non-sticky state 
of the material.  The working phase (2-4 minutes) is the period in which the cement is 
injectable and should be used by the surgeon to manipulate the cement and place it in the 
joint.  The last phase is the hardening phase (1-2 minutes) and is the period of final 
setting and the development of the heat of polymerization [4].  Viscosity is the most 




The viscosity of bone cement is determined by the chemical composition and the powder 
to monomer ratio.  There are typically two categories of bone cements:  high and low 
viscosity.  High viscosity bone cements have short wetting phases, lose their stickiness 
quickly, have a shorter waiting phase, are injectable almost directly after mixing, and 
have a longer handling time.  Low viscosity bone cements have a long lasting liquid to 
low viscosity wetting phase and the material usually remains sticky for three minutes or 
longer.  Common high and low viscosity cements are displayed in Table 1.1.  Viscosity 
of the initial mixture should be low enough to allow material insertion in the bone 
cavities.  When curing starts, monomer is rapidly consumed by the propagation reaction 
and the viscosity increases [29].    
 
Table 1.1  Current Bone Cements 
Brand V iscosity Manufacturer Location 
Palacos R 
High 
Zimmer Warsaw, Indiana, US 
Palamed Heraeus Wehrheim, Germany 
Smartset HV DePuy Warsaw, Indiana, US 
Cemfix 1 Teknimed Vic en Bigorre, France 
Osteopal 
Low 
Zimmer Warsaw, Indiana, US 
Palacos LV Heraeus Wehrheim, Germany 
Simplex P Stryker Limerick, Ireland 
Osteobond Zimmer Warsaw, Indiana, US 
Versabond Smith & Nephew Memphis, Tennessee, US 
Cemfix 3 Teknimed Vic en Bigorre, France 
 
All of these manufacturers produce slightly different products.  Each bone cement 
formulation has generally the same composition but there are slight differences that 
impact the properties of the bone cement.  These differences can include type and amount 
of copolymer, powder particle size, type and amount of radio pacifier, percentage of 
initiator (BPO), exact chemical formulations, sterilization method, polymerization 
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reactions, and setting times.  In these studies we used two of the above listed cements, 
one of each viscosity.  The two cements were chosen because of their differering 
viscosities, handling types, and market share.   
 
Another way commercialized cements differ is by molecular weight.  Molecular weight is 
the characteristic parameter for the length of the polymer chains incorporated in the 
polymer powder or resulting from the polymerization of the MMA.  Molecular weight 
influences the swelling properties and the mechanical properties of the bone cement.  The 
molecular weight of the polymer powder is affected by the type of sterilization procedure 
used.  Sterilization by γ-irradiation or β-irradiation significantly lowers the molecular 
weight of the cement. Ethylene oxide sterilization has no influence on the molecular 
weight of the polymer or change any material properties, but it is more complex, time-
consuming, and therefore more expensive [4].   
 
Another variation in cement formulation is mixing method.  This is an aspect that has 
been extensively studied.  Hand mixing is generally defined as mixing in a ceramic bowl 
with a metal spatula at stirring frequency of 1-2 Hz.  Mixing time is typically one minute.  
This type of manual mixing method has been shown to create cement mixtures that are 
porous and contain voids.  These voids and pores decrease the mechanical integrity of the 
cement and can lead to fatigue fractures.  Mixing methods that lead to a more efficacious 
bone cement mantle include mechanical mixing, vacuum mixing, or centrifugation.  
Vacuum mixing systems typically have a fixed central axis.  The cement is mixed for one 
minute under a pressure of about 300 mmHg.  Additional vacuum mixing setups can 
include a rotating-central axis.  In this setup the same mixing procedure is followed.  
Manual mixing decreases the amount of unmixed powder but vacuum mixing decreases 
the number of voids in the mixture [30].  The variations caused by mixing must be taken 
into account in relation to how the cement is going to be used.  
 
Acrylic bone cement is the only material used for anchoring a total joint prosthesis to the 
contiguous bone in a cemented arthroplasty.  It has drawbacks including thermal necrosis, 
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chemical necrosis, cement shrinkage, and uneven peri-prosthetic cement distribution.  
Cement shrinkage can lead to loosening, and thereby reduce the clinical life of the 
arthroplasty.  The mechanical properties of the cement will also be affected.  The 
resistance to fracture at both the cement-prosthesis and cement-bone interface can be 
decreased.  Despite the drawbacks, the success rate of arthroplasties is very high.  At least 
ninety percent of implanted cemented hip and knee arthroplasties in patients over fifty 
years old were successful in maintaining their results over time without deterioration 
[31]. 
 
Section 1.2.4   Antibiotic Laden Bone Cement 
 
Bacterial infections during orthopaedic surgery can come from the atmosphere in the 
operating room, surgical equipment, and resident bacteria on the patient’s skin or already 
in the body.  Device-associated infections are the result of bacterial adhesion or biofilm 
formation at an implantation site.  One of the most critical steps in preventing implant-
associated infection is the inhibition of bacterial adhesion [32].  The pathogenesis of post-
implant infections differs from other post-surgical infections because of the presence of 
biomaterials.  The interstitial milieu surrounding prosthetic implants is known to 
represent a region of local immune depression and is often referred to as immuno-
incompetent fibro-inflammatory zone [33].  When strange materials are implanted into 
the human body an inflammatory response known as the foreign body reaction develops.  
Therefore, any material that is applied to the human body should be able to perform with 
an appropriate host response, or show a high degree of biocompatibility [5].  Bone 
cement is one of these materials.   
 
A prosthesis-related infection is difficult to treat.  With modern standards and improved 
sterility within the operating room environment and peri-operative antibiotic prophylaxis, 
the incidence of infections associated with orthopaedic implants has become very low.  It 
leads to complex revision procedures, failure of the implant, and possibly the need for 
complete removal of the implant.  Standard antibiotic protocols that are effective against 
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other infections fail in these cases.  Typical treatment involves the removal of the 
infected prosthesis.  Antibiotic treatment can then be successful once the foreign body 
materials have been removed.  These antibiotics can be administered systemically or 
locally.  Local administration of antibiotics can be achieved by implanting antibiotic-
releasing carriers such as antibiotic bead chains or antibiotic-loaded bone cement [34, 
35].  Thermostable antibiotics are added to PMMA and leached out into the blood stream.  
These methods aim to reach and maintain local antibiotic concentration at a level that 
cannot be attained using systemic administration without side effects [5].     
 
The most extensively studied and earliest commercially available device for controlled 
release of antibiotics was developed in the 1970’s by Buchholz and Engelbrecht [36].  
They had the idea of releasing antibiotics from the newly introduced non-biodegradable 
polymethylmethacrylate (PMMA) bone cement.  Antibiotic bone cement is still widely 
accepted as a way to reduce bone infection.  Buchholz reported in 1981 that there was a 
success rate of 77% for exhange arthroplasty where the old prosthesis was replaced by a 
new one that was cemented with antibiotic-loaded bone cement [37].  Performing a 
second exchange arthroplasty increased the success rate to 90% [38].  There are some 
drawbacks to this device:  PMMA enables only a small fraction of the antibiotic to 
diffuse through the polymer pores [39-41] and it may possibly house resistant bacteria.  
Also, since PMMA is not biodegradable, when clinical failure occurs, a secondary 
surgery may be necessary to remove the PMMA before bone can regenerate.  In the bone 
cement systems with antibiotics, the soluble drug is slowly released from the polymerized 
bone cement surrounding the implant.  Incorporation of antibiotics into bone cement is 
currently limited to antibacterial drugs that are able to withstand the heat generated by 
polymerization [32].  Loaded drugs are released through mechanisms of water pore 
penetration, soluble matrix dissolution, and outward diffusion of solubilized drug via 
matrix imperfections.  The typical release pattern is characterized by an initial burst 
release followed by a long tail of low, ineffective, and largely incomplete release that 
continues for days or months.  A number of studies have shown that less than 10% of the 




Studies of antibiotic-laden bone cement and the elution characteristics of specific 
antibiotics from bone cement have been ongoing for over thirty years.  Using bone 
cement as a reservoir for antibiotics, allows for antibiotics to be delivered immediately 
and locally.  It is fully accepted that antibiotic substances mixed in powder form with the 
prepolymerized polymer powder before mixing with liquid monomer elute after curing 
from the surface into an aqueous medium.  The process is largely diffusion and the rate 
depends on the chemical composition of the cement, the concentration of the antibiotic, 
the surface area of the exposed cement, the rate at which the eluent is cleared from the 
surface, and the chemical stability of the antibiotic itself [2, 36, 38, 42].  Antibiotics are 
released from bone cement in a bi-phasic fashion.  There is peak release initially, 
followed by a long low release that continues for days or months.  As the amount of 
antibiotic included in the cement is increased, the relative amount released also increases.  
It is accepted that the local concentrations of antibiotic eluted during the first days of 
implantation are vastly greater than those available from systemic administration [43].   
 
Gentamicin is one of the most common antibiotics included in commerical antibiotic-
loaded bone cements.  It has wide-spectrum antimicrobial activity, is water soluble, has 
thermal stability, and low allergenicity [35].  Gentamicin is a naturally occurring 
antibiotic produced by the bacterial strain Micromonospora purpurea and has been in 
clinical use for over 50 years [44].  It is an aminoglycoside that has concentration-
dependent antibacterial activity.  If the antibiotic concentration is high enough, all the 
bacteria will die within a short period of time.  Another antibiotic that is commonly used 
in loaded bone cements is Tobramycin.  Tobramycin is an aminoglycoside antibiotic that 
is used to treat gram-negative bacterial infections.   
 
Bone cement with the addition of antibiotic has become a standard practice in Europe and 
Scandinavia, for both primary and revision knee and hip arthroplasties.  In Norway, the 
use of antibiotic-containing bone cement increased from approximately 40% in 1987 to 
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90% in 1998 in total hip arthroplasties [18].  In 2004, the United States Food and Drug 
Administration approved antibiotic bone cement use in infected total joint arthroplasties.   
Prevention of infection would save the patient significant morbidity and the health care 
system significant costs [19].  The current average cost of treating an infection at the site 
of a total joint arthroplasty is approximately $60,000, with an average net loss to the 
hospital of $20,000 per patient [16].  Much has been done to improve operating 
procedures to minimize contaminiation and bacterial exposure.  The use of antibiotic 
bone cement was found to be cost-effective in eliminating infection and reducing the 
costs of difficult revisions [18].   
 
Section 1.2.5   Variations and Adaptations 
 
Through the years, surgeons and researchers investigated the different ways bone cement 
is prepared and the possible additions to the bone cement material that could be made.  
The common components of cement have also been investigated individually to 
determine what happens to the cement’s material properties when their amounts and 
ratios are changed.  Simplex P cement reduced the N,N-dimethyl-para-toluidine (DMPT) 
content from 2.5 vol% to between 0.8-1.4 vol%.  This resulted in a cement with 
approximately 54% higher setting time, 7% lower maximum exotherm temperature, 4% 
lower ultimate compressive strength, and the computed polymerization rate at 37oC (k’) 
was approximately 97% lower [11].  The increased setting time puts this type of cement 
at the maximum limit recommended per ISO 5833 standards (14 minutes).  This may 
pose a problem during preparation and handing for use in a cemented total joint 
replacement.  The increasing handling time may cause economic burden because of the 
cost per minute in the operating room, scheduling limitations, and additional employee 
wages. 
 
It has been identified that the presence of radiopacifiers in the cement mixture influences 
different mechanical properties of bone cement including tensile strength, flexural 
strength, and fracture toughness.  In tensile strength testing it was seen that the addition 
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of barium sulphate particles significantly decreased tensile strength.  This was not seen in 
ZrO2, possibly because of the different size and shape of these particles.  The barium 
sulphate particles tended to form agglomerates and didn’t seem to anchor themselves to 
the polymer matrix like the zirconium dioxide agglomerates.  Zirconium dioxide cement 
and barium sulfate cement were found to improve fatigue crack propagation resistance 
[45]. 
 
One of the components of bone cement that is less studied is the effect of initiator 
benzoyl peroxide on curing parameters and mechanical properties.  Samples with lower 
BPO concentrations had the highest amount of residual monomer present.  This may act 
as an internal plasticer that allows the molecules to reach higher deformation before 
failure.  As the concentration of BPO increased, the polymerization exotherm was 
increased, accompanied with a shorter dough time and less residual monomer.  The mean 
ultimate tensile strength and the Young’s modulus were found to increase with increasing 
BPO concentration until 2 wt%.  During the initiation process of mixing, the DMPT is 
the active ingredient that induces reaction of the BPO which produces free radicals 
capable of initiation polymerization.  The efficiency of these free radicals falls between 
50 and 80%.  BPO and DMPT concentrations are the variables that essentially control the 
rate of polymerization.  Peak temperature is expected to increase and the setting time to 
decrease by increasing both the DMPT and BPO concentrations.  The peak temperature 
decreased with decreasing BPO concentration.  The difference in peak temperature for a 
formulation with a 2 wt% BPO concentration and a formulation with 0.75 wt% was 10oC.  
This decrease should not be neglected as any decrease in peak temperature is beneficial to 
the reduction of long-term necrosis.  The setting time increased with decreasing initiator 
concentration, with a difference of about 5 minutes between the highest and lowest BPO 
concentrations.  Also, as found in literature, the addition of barium sulphate did not affect 
the curing characteristics of the cement but did affect the mechanical properties.  An 
optimum of 1.5% by weight of benzoyl peroxide was found to yield suitable handling 




In more recent years, surgeons and engineers also began adding elements to bone cement 
to increase their mechanical strength, fatigue life, or ability to prevent infection.  Gladius 
Lewis reviewed many of the different commercial cements, including reinforced cements 
[11].  In one sample set, PMMA matrix was reinforced with 0.5-10 wt% multi-walled 
carbon nanotubes.  Two weight percent was found to be the optimum reinforcement mass 
percentage based on the values of mechanical properties [11].  With this loading, the 
nanotubes have their long axis oriented to the plane of the incipient crack, and there is an 
absence of inadequately dispersed nanotubes, as was seen at higher loading.  For 
reinforced cements in general, fatigue life, fracture toughness, ultimate tensile strength, 
and ultimate compressive strength were improved over control cements.  However, for 
flexural strength, there was little or no gain.  There are some problems with reinforced 
cements, although literature contains very little or no discussion of these main challenges.  
Those challenges include being able to develop accurate methods of blending the 
reinforcing agent with the matrix to insure that the agent does not aggregate, obtaining 
perfect bonding between the reinforcing agent and the matrix so that there are no crack 
initiation sites at the agent-matrix interface, and limiting the viscosity of the curing 
cement to keep its handling easy.  Also, it must be ensured that the interstices of the bone 
are completely free, to try to achieve a perfect cement-bone interface [11].   
 
One of the reasons fibers are used to reinforce bone cement is that it is believed that they 
will increase the fracture toughness properties of bone cement which can prevent failure 
within the bone cement mantle.  The fracture toughness of a polymer (PMMA) can also 
be increased by increasing the molecular weight of the polymer [47].  Fiber 
reinforcements of bone cement may be a more practical route to enhance the fracture 
resistance of bone cement along with increasing the actual strength of the cement.  Using 
fibers with a higher heat capacity has the potential to decrease the peak temperatures 
observed in the surrounding bone tissue during cement curing [48].  One of the concerns 
with adding fiber reinforcements to the polymer matrix is that the viscosity of the cement 
becomes too high to work in a cement gun.  Titanium fibers added at 5% to the 
polymerizing matrix of bone cement were shown to increase the fracture toughness of the 
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bone cement without significantly affecting the viscosity [49].  Steel has higher 
volumetric heat capacity than titanium so any temperature reduction would be larger for 
steel-reinforced bone cement.  Steel also has high fracture toughness, a large energy 
absorption capacity, and it will undergo 30-60% plastic deformation before failure.  Steel 
fibers ranging in diameter from 21.9-52.4 µm and in length from 1-3 mm have been used 
to augment cement [48].  Fracture toughness of the bone cement was increased by at least 
78% and increased as the volume fraction of fibers increased.  SEM results of the 
fractured ends revealed pull-out regions, which indicated that the bonding between the 
fibers and the matrix is not good.  The peak temperatures obtained during curing were 
decreased in the steel-fiber-reinforced samples [48].   
 
Section 1.3   Carbon Nanotubes  
 
Section 1.3.1   History and Properties 
 
Carbon nanotubes can be traced back to fullerene chemistry (buckyball, C60) in 1985.  
Carbon nanotubes themselves were discovered by Iijima in 1991.  Their discovery has 
lead to significant scientific, engineering, and medical research about these materials and 
in discovering ways to use them.  Carbon nanotubes (CNTs) are long cylinders of 
covalently bonded carbon atoms.  Every carbon atom is connected to three other carbon 
atoms in a perfect network.  This perfect molecular network, allows nanotubes to 
maintain their identity up to temperatures around 212oF [50].  There are two types of 
carbon nanotubes:  multi-walled carbon nanotubes (MWNTs) and single-walled carbon 
nanotubes (SWNTs).  MWNTs consist of two or more concentric cylindrical shells of 
graphene sheets coaxially arranged around a central hollow core with interlayer 
separations.  Figure 1.1 shows a transmission electron micrograph (TEM) of the walls of 
a multiwall carbon nanotube.  MWNTs are flexible and resilient [51] hollow tubular 
structures that have diameters from several nanometers to several hundred nanometers 
[52] and are 10-100 µm long [53].  SWNTs have a single graphene cylinder and have an 
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average diameter of 0.4 to 3 nm [52, 53].  MWNTs have physical characteristics of solids 
and are micro-crystals with high aspect ratios of 1000 or more [54].   
 
 
F igure 1.1  Transmission electron micrograph of the walls of a multiwall carbon 
nanotube with an outside diameter of ~20 nm [Reprinted from Carbon, 45, Brock Marrs, 
Rodney Andrews, and David Pienkowski, Multiwall carbon nanotubes enhance the fatigue 
performance of physiologically maintained methyl methacrylate-styrene copolymer, Page 2099, 
Copyright 2007, with permission from Elsevier]. 
 
The structure and properties of carbon nanotubes have been analyzed using direct 
measurement and modeling techniques.  Their properties are remarkable and have led to 
their use in a wide variety of application.  Carbon nanotubes have extraordinary 
mechanical properties, including exceptionally high tensile strength and stiffness.  They 
have tremendously high strength, are 50 to 100 times stronger than steel at one-sixth the 
weight of steel [55], have an on-axis thermal conductivity that rivals that of diamond [50] 
and remarkable magnetic properties (due to encapsulated catalyst metals) [50].  Table 1.2 
displays some of carbon nanotubes’ theoretical and experimental properties.  The 
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electronic properties of perfect MWNTs are similar to perfect SWNTs because the 
coupling between the cylinders is weak in MWNTs.  Electronic transport basically occurs 
ballistically (no scattering) over long nanotube lengths, enabling them to carry high 
currents with essentially no heating [56].  The measured room temperature thermal 
conductivity for an individual MWNT (>3000 W/m K) is greater than that of natural 
diamond or the basal plane of graphite (2000 W/m K) [57].   
 
Table 1.2  Properties of Carbon Nanotubes [54] 
Property SW N Ts M W N Ts 
Elastic modulus 1 TPa 0.3-1 TPa 
Strength 50-500 GPa 10-60 GPa 
Resistivity 5-50 µΩ cm 5-50 µΩ cm 
Thermal conductivity 3000 W/mK 3000 W/mK 
 
Carbon nanotubes have huge industrial application potential and are therefore being 
extensively researched for a variety of industries, products, and other uses.  The global 
market for carbon nanotubes was estimated at $12 million for 2002 and expected to grow 
up to $700 million by 2005 [58].  Electronics.ca published a report stating that the global 
carbon nanotube market is projected to exceed $1.9 billion by 2010.  This would be a 
compound annual growth rate of more than 80% during the analysis period.  The MWNT 
market was estimated at $290 million for 2006.  The revenues from these materials are 
higher due to their simple production and low cost when compared to SWNTs [58].   
 
Section 1.3.2   Carbon Nanotube Composites 
 
The fiber-like structure of carbon nanotubes, their low density, high aspect ratio, and 
extraordinary mechanical properties make them particularly attractive for reinforcement 
in composite materials [52].  The conductivity, strength, elasticity, toughness, and 
durability of a composite material can be substantially improved with the addition of 
carbon nanotubes [50].  The first realized major commercial application of MWNTs was 
in polymer composites.  Polymer and carbon nanotube composites began as a NASA 
research project for a variety of applications.  They found the composites had unique 
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mechanical, surface, and multi-functional properties; and strong interactions with the 
matrix because of the nano-scale microstructure and extremely large surface area [54].   
The properties of nanotube/polymer composites vary significantly depending on the 
distribution, the type, diameter, and length of the nanotubes.  Polymer nanocomposites 
also depend on several factors including but not limited to the process used to produce 
nanotubes, nanotube purification, and amount of impurities, nanotube size, aggregation, 
and nanotube orientation [59].  The combination of carbon nanotubes’ superlative 
mechanical, thermal, and electronic properties makes them an ideal candidate as an 
advanced filler material in nanocomposites [60].   
 
Carbon nanotube composites have higher shear stress values than traditional fiber 
composites, possibly due to good bonding between the nanotubes and polymer matrix.  
Incorporation of nanotubes into plastics can provide structural materials with 
dramatically increased modulus and strength [54].  Depending on the polymer matrix, 
conductivities of 0.01 to 0.1 S/cm can be obtained for 5% nanotube loading.  The low 
loading levels and the nanofiber morphology of the MWNTs allow electronic 
conductivity to be achieved while avoiding or minimizing degradation of other 
performance aspects, including mechanical properties and viscosity.  The critical 
challenges lie in uniformly dispersing the nanotubes and achieving nanotube-matrix 
adhesion to provide effective stress transfer [56].  The thermal transport properties of 
CNT polymer composites could also improve due to the excellent thermal conductivity of 
CNTs [54].  This offers an opportunity for CNT polymer composites in a variety of 
different uses.   
 
The high modulus and low weight of carbon fibers make them ideal reinforcing agents in 
a variety of composite materials.  To take advantage of the high Young’s modulus and 
high strength of carbon nanotubes the load transfer efficiency is very important.  If the 
adhesion between the matrix and the carbon nanotubes is not strong enough to sustain 
high loads, the benefits of the high tensile strength of carbon nanotubes are lost.  One of 
the ways to improve adhesion and shear strength is to functionalize the nanotubes, or 
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increase the surface roughness or surface reactivity [61].  Functionalization may slightly 
lower the thermal conductivity of the MWNTs, but the property is so significant that it 
can still be exploited to make thermally conductive composites [62].  Effective 
reinforcement of a polymer with carbon nanotubes requires four things:  large aspect 
ratio, good dispersion, alignment, and interfacial stress transfer.  The aspect ratio must be 
large to maximize the load transfer to the nanotubes to optimize composite strength and 
stiffness.  Carbon nanotubes must also be uniformly dispersed as isolated nanotubes 
individually coated with polymer.  This is important to achieve efficient load transfer to 
the nanotube network.  A more uniform stress distribution is achieved as a result, and the 
presence of stress-concentration centers is minimized [60].   
 
The most important part of making a successful composite is the complete and effective 
dispersion of the nanotubes through the matrix without destroying the integrity of any of 
the involved materials.  To maximize the advantage of CNTs as effective reinforcements 
in high strength composites they should not form aggregates and must be well dispersed 
to prevent slippage [63].  There are several techniques to improve the dispersion of CNTs 
in polymer matrices, such as by optimum physical blending, in situ polymerization, and 
chemical functionalization [54].  One effective method found for dispersion of MWNTs 
is shear mixing [59].  High shear mixing energy resulted in more uniform dispersion but 
the MWNTs were broken.  The dispersion of nano-fillers in polymer matrices is more 
difficult than that of micro-fillers due to the strong tendency to agglomerate in the nano-
fillers [54].  Dispersion of CNTs is crucial to the production of both a homogenous 
product and to composite performance.  Dispersion of CNTs in composites was 
determined quantitatively by Andrews’ group by optical microscopy of polished sections.  
The group investigated the uniformity of fiber distribution across the specimen and the 
frequency of agglomerates in the matrix using the microscope.  At any given temperature, 
the dispersion efficiency can be related to the mechanical energy input into the mix.  
Increasing either the residence time and/or rotor speed can increase the energy input and 
therefore improve the dispersion.  When low concentrations (<0.5 vol%) of MWNTs are 
dispersed into polymers, a remarkable reduction in surface electrical resistivity can be 
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produced.  But there is generally only a small increase in elastic modulus and a decrease 
in tensile strength.  The reduction in tensile strength can be attributed to an increase in the 
frequency distribution of defects associated with the nanotubes that initiate failure or 
attributed to the poor interfacial bonding between the nanotubes and the matrix and the 
absence of alignment of the fibers in a preferred direction [59].  At higher concentrations 
of MWNTs the stiffness and strength of the composites were significantly improved [64]. 
 
The quality of nanotube dispersion in polymer matrices can be determined using scanning 
electron microscopy (SEM), as well as optical microscopy, polarized Raman imaging, 
and transmission electron microscopy (TEM).  Gaps in expected mechanical properties 
especially for lower percentages of CNTs in composites can be explained by imperfect 
dispersion of CNTs and poor load transfer.  Agglomeration leads to defect sites in the 
composites and limits the efficiency of carbon nanotubes on the polymer matrices.  Poor 
dispersion and rope-like entanglement of CNTs leads to drastic weakening of the 
composites.  Alignment of CNTs in the polymer plays a role in the mechanical and 
functional properties of composites [54].  Even modest nanotube agglomeration impacts 
the diameter and length distributions of the filler and overall is likely to decrease the 
aspect ratio.  Nanotube agglomeration reduces the modulus of the filler relative to that of 
the isolated nanotubes because there are only weak dispersive forces between nanotubes 
[52].   
 
The toxicity of carbon nanotubes in terms of medical use is less studied.  Past reports 
tended to report negative conclusions about carbon nanotubes and their potential use in 
the human body.  Authors suggested that carbon nanotubes were toxic to humans and that 
strict industrial hygiene measures should be taken to limit exposure during production 
and handling.  One study published in 2005 showed that multiwall carbon nanotubes that 
were administered intratracheally to rats induced inflammatory and fibrotic reactions in 
the animals, as well as pulmonary lesions and agglomerates of nanotubes in the airways 
[65].  Current research shows that if certain precautions are taken in carbon nanotube 
production they are less harmful to humans.  One of those precautions is 
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functionalization.  This involves chemical modification and solubilization of single-
walled and/or multi-walled carbon nanotubes [66].     
 
Many researchers have tried to improve the mechanical properties of bone cement by 
adding small amounts of other materials including metal, glass, polymer, or carbon fibers.  
These efforts typically had little success because of inadequate dispersion, poor fiber-
matrix bonding, and filler-damage scale mismatch.  Scale compatibility was one of the 
reasons that led to the discovery of MWNTs as a reinforcement material for bone cement. 
Their small diameters are far more comparable to the size of the polymer chains and the 
scale of fatigue damage.  There is increased physical interface between the MWNTs and 
the polymer matrix because of the large surface area to volume ratio of the MWNTs [67].  
Acrylic bone cement has been shown to have less than ideal resistance to mechanical 
fatigue and impact, but carbon nanotubes can substantially improve these mechanical 
properties because of their prodigious tensile strength and large surface area to volume 
ratio which confers outstanding nanotube-cement matrix bonding [55].  Although 
improved surgical technigue has increased the probability of prosthesis survival, reducing 
or eliminating bone cement fracture by improving the material would further enhance the 
longevity of cemented prostheses [68].   
 
Previous work produced by members of our laboratory showed that bone cement can be 
successfully loaded with MWNTs.  The MWNTs improved the mechanical properties 
and fatigue life of the bone cement material [67].  The methods and results of their 
experiments are described as follows.  MWNTs were synthesized by the University of 
Kentucky’s Center for Applied Energy Research using a chemical vapor deposition 
process where a mixture of ferrocene catalyst and xylene were injected into a multi-zone, 
heated furnace under a hydrogen-argon (10-90) atmosphere (675 cm3/min) [67].  Iron 
from the decomposed ferrocene acted as a catalyst for the formation of the ordered lattice 
structure of the carbon nanotubes.  The carbon nanotubes were then harvested in clusters 




Marrs et al dispersed MWNTs throughout the molten matrix of pre-polymerized methyl 
methacrylate and styrene (MMA-co-Sty) copolymer powder.  The mixture was subjected 
to high-shear mixing with two heated (220oC) stainless steel, counter-rotating sigma 
rotors in the mixing chamber of a Haake Rheomix (Haake, GMBH, Germany).  The bone 
cement powder was added to the mixing chamber followed by the as-produced MWNTs.  
The materials were shear mixed by the sigma rotors to disentangle and thoroughly 
disperse the MWNTs throughout the molten polymer.  Nanocomposites consisting of 0.5, 
1, 2, 5, and 10 wt% MWNTs were produced using a dilution method.  The molten 
material was collected and allowed to cool.  The hard composite materials were then 
crushed and sieved to a particle size of equal to or less than 2 mm.  A 12-ton laboratory 
press was used to hot-press the crushed particles into films of uniform thickness (1.6 mm) 
under vacuum [55].  The films were then machined into dog-bone-shaped specimens and 
bar shaped specimens, which were then annealed to remove any surface flaws and to 
alleviate any residual stresses that formed during machining.   
 
After curing at room temperature for 24 hours, the bar specimens were tested to failure in 
3-point bending using a Q TestTM 10 Elite (MTS Inc., Minneapolis, MN) materials testing 
system.  The flexural strength, flexural yield strength, bending modulus, and strain were 
recorded for each specimen.  Fatigue testing in 4-point bending was then performed in air 
at room temperature on an Instron 1331 (Instron Corp., Canton, MA) servohydraulic 
materials testing system.  A sinusoidal wave profile was applied with a minimum load of 
4 N and a maximum load of 40 N at a frequency of 5 Hz.  The number of cycles to failure 
was recorded for each specimen.  The 2 wt% MWNT composite was found to be nearly 
optimal for 3-point bend mechanical properties.  Flexural strength was enhanced by 
12.8% and flexural yield strength was enhanced by 13.1%.  The 2 wt% MWNT 
concentration also had a 3.1-fold increase in the mean actual fatigue life.  Bone cement 
samples with small weight percentages of MWNTs were found to have enhanced flexural 




SEM images of the fractured surface of fatigue-failed specimens showed the MWNTs 
protruding from the bone cement matrix as long finger-like projections.  Visually the 
nanotubes appeared to be randomly spaced but aligned along the direction of loading.  It 
is believed that the MWNTs reoriented so that they offered resistance to crack growth by 
spanning the crack in a direction perpendicular to the plane of crack growth [55].  This 
should occur because of the nanotubes being well-dispersed, the anticipated strong 
nanotube-matrix as a result of their high surface area to volume ratio, and their extremely 
strong tensile properties.  The nanotubes would slow crack growth and enhance the 
longevity of the cement mantle [55].  It was suggested that decreases in material 
properties with larger MWNT concentrations is a result of agglomerated or clumped 
MWNTs in the composite.  These agglomerations may act as fracture initiation sites.  If 
there are enough of them, there may be enough detrimental effects that the beneficial 
effects of the MWNTs are eliminated [55].   
 
The fatigue specimens were measured and aged in phosphate buffered saline (PBS) at 
37oC for 6-60 days [67].  Fully reversed tension-compression fatigue testing was 
performed in a heated (37oC) PBS environment with an Instron 8521 servohydraulic 
materials testing system (Instron Corp., Canton, MA).  Specimens were sinusoidally 
loaded at 5 Hz to peak tensile/compressive stress amplitudes of 20, 30, and 35 MPa until 
failure or 2 million cycles.  SEM was used to examine individual MWNTs within the 
nanocomposite matrix after fatigue testing.  Testing at the 20 MPa peak stress amplitude 
showed that the 2 wt% and 5 wt% MWNT samples had 565% and 592% greater fatigue 
lives, respectively, when compared to the control group.  The 0.5 wt% had the smallest 
increase but the value was still 307% greater than the control samples.  At large 
percentages of MWNTs, the results were less than ideal.  The irregularities with those 
results are believed to be due to imperfectly disaggregating and dispersing the larger 
amounts of MWNTs into the MMA-co-Sty matrix.  Examination of the SEM crack 
images showed the MWNTs protruding from the cracked faces in the normal direction to 
crack growth, shown in Figure 1.2.  Some of the MWNTs were seen to bridge the 
growing crack.  Multiwall carbon nanotubes were shown to clearly enhance the fatigue 
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performance of MMA-co-Sty.  MWNTs retard the mechanism of fatigue failure by 
preventing or minimizing the initiation of catastrophic cracks and by slowing damage to 
the accumulation of existing or newly forming cracks [67].  The MWNTs were believed 
to bridge cracks and reduce the extent of plastic deformation experienced by the matrix.  
The effectiveness of MWNTs as reinforcement is dependent on the concentration of 
MWNTs, their dispersion, and the peak stress of the dynamic loading cycle.   
 
 
F igure 1.2  SEM images showing the growth of one micro-crack (a) on the surface of 
one of the 5 wt% MWNTs specimens that had been stressed at 20 MPa.  Images (b), (c), 
and (d) showed the MWNT matrix-reinforcing behavior across the crack [Reprinted from 
Carbon, 45, Brock Marrs, Rodney Andrews, and David Pienkowski, Multiwall carbon nanotubes 
enhance the fatigue performance of physiologically maintained methyl methacrylate-styrene 






The addition of carbon nanotubes to bone cement may also offer thermal benefits to the 
cement to enhance implant longevity.  The high temperatures seen at cement-bone 
interfaces during in vivo polymerization could be lowered as a result of the high axial 
thermal conductivity of MWNTs.  The addition of steel fibers (5-15%) reduced the peak 
temperature of curing PMMA [48].  The addition of MWNTs to bone cement may help 
avoid polymerization induced “hot” spots and subsequent hyperthermia-based destruction 
of bone adjacent to the cement mantle.  The mechanical integrity of the cement-bone 
interface may be improved and the implant performance enhanced [55].   
 
Section 1.4   Objectives  
 
The goals of this thesis are:  1) to determine if MWNTs change the flow of heat in 
polymerizing bone cement, and if so, what are the kinetics of this alteration and 2) to 
determine if MWNTs alter the flow of heat in antibiotic laden bone cement, and if so, to 






Chapter 2 - Polymerization K inetics of Acrylic Bone Cement with 
Multiwall Carbon Nanotubes 
 
Section 2.1   Introduction 
 
The properties and performance of acrylic-based bone cements and the supporting bone 
are strongly dependent on the polymerization kinetics including the chemical reaction of 
the MMA monomer [69].  The polymerization kinetics of bone cement must be 
determined to study the thermal behavior of a bone-cement-prosthesis system.  The 
progress of the polymerization reaction can be seen in the temperature rise in the bone 
cement mixture due to the exothermic polymerization of MMA [70].  Polymerization 
kinetics, and the amount of left over monomer, depend on the temperature of the 
polymerizing material.  The temperature distribution during polymerization is one of the 
most important determinants for the success of the cementation procedure [71].  The 
exothermic polymerization reaction, coupled with the poor heat conductivity of PMMA, 
has been theorized to result in localized “hot spots” which nucleate small voids.  These 
voids can then later become sites for the initiation of fatigue cracks which ultimately lead 
to mechanical failure of the cement and implant loosening.  The hot spots are caused by 
poor heat dispersion across the polymer.  Polymerization occurs almost sporadically in 
the bone cement material.  Failure and loosening of an implant will force the patient to 
undergo a painful, costly, and difficult revision surgery. 
 
The heat generated during polymerization causes a temperature increase in the whole 
system.  The peak temperatures are first located at the cement/bone interface and then 
move into the middle of the cement over the course of the reaction.  The temperatures are 
highest in this region because the temperature of the bone is higher than the temperature 
of the implant.  The higher bone temperature aids in the polymerization kinetics of the 
bone cement.  When a balance between heat generation and thermal conduction is 
obtained, the temperature reaches a maximum and is subsequently followed by cooling as 
the conduction dominates the reaction [70].  The temperature of the mixture drops after 
the polymerization reaction is completed.  The heat is dissipated into the surrounding 
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environment.  The temperature of bone tissue surrounding the bone cement increases due 
to the heat released by the curing bone cement [70].   
 
Toksvig-Larsen completed a study to investigate the temperatures experienced at the 
cement interface in hip arthroplasties.  Temperature measurements were performed with 
thermocouples with a range of 0-110oC with a total accuracy of ±1 oC.  The 
thermocouples were placed so that their tips laid flush with prepared bone surface.  The 
points of measurement included the middle of the circumference of the acetabulum and 
the trochanteric region of the femur.  The mean maximum cement-curing temperature in 
the acetabulum was 43oC (109.4 oF) and 40oC (104 oF) in the femur.  In the acetabulum, 5 
of 28 recordings were above 44oC and 2 of 28 recordings were above 47 oC.  In the 
femur, 4 of 41 recordings were above 47 oC.  The longest duration above 44oC was 7 
minutes and above 47oC was 2 minutes and 20 seconds [72].  In 1984, Eriksson found the 
threshold temperature for impaired bone regeneration to be in the range of 44-47oC when 
measured at a distance of 0.5 mm and applied for 1 minute [73].  There are many factors 
that influence the rate of build-up and dissipation of the amount of heat generated during 
bone cement polymerization.  These factors include the rate of setting, the size and shape 
of the bone cement mass, and the thermal properties of the surrounding materials – 
including bone, blood, and the plastic and metallic components of the prosthesis [72].   
 
Thermal factors, such as thermal injury to the periprosthetic tissues and osseous necrosis 
of those tissues can lead to aseptic loosening of cemented arthroplasties.  This is a 
complex phenomenon that is also believed to be affected by mechanical factors, such as 
fatigue failure that occurs due to crack growth from voids.  Thermal injury is associated 
with the high heat produced during the in situ polymerizing of the cement [28, 74].  
Osseous necrosis results from leakage of unreacted or residual monomer from the cured 
cement to the surrounding tissues [31, 75].  It is also believed that a lower polymerization 
reaction rate (k) and a higher degree of monomer conversion will lead to a smaller 
amount of residual monomer [29].  This will contribute to long-term in vivo stability of 





polymerization reaction rate.  Those three variables included the amount of copolymer as 
a proportion of the total powder weight (COP), the amount of DMPT as a proportion of 
the total volume of the liquid monomer (ACC), and the accelerator.  The study was 
completed using differential scanning calorimetry (DSC) in the nonisothermal mode [13].  
DSC measurements may be used for determining the progress of curing of bone cement 
by assuming that the heat evolved during the polymerization reaction is directly 
proportional to the overall extent of the reaction.  For each of the cements, the correct 
ratio of powder to liquid according to manufacturer was manually mixed in a 
polyethylene bowl that was open to ambient air for 1 minute.  A spatula was used to 
transfer approximately 3 mg of material very quickly to the center of a DSC aluminum 
sample pan.  The sample pan was situated in a DuPont 910 DSC (Instrument Specialists, 
Spring Grove, IL) that was operating under a nitrogen purge, with a constant flow rate of 
100 cm3 min-1.  The DSC test was conducted immediately to prevent complete curing of 
the cement prior to test start.  The pan was heating in the chamber from the initial dough 
temperature, Ti, to a final temperature, Tf, of 150oC at a predetermined rate of heating.  Ti 
was taken to be the temperature of the air in the room, 23oC±1oC.  The exothermic heat 
flow from the polymerizing cement (H) was recorded as a function of its temperature (Td) 
during the heating period.  This is known as a thermogram.  A variety of different heating 
rates were used, including 5, 10, 15, and 20 K min-1.  At each heating rate triplicate DSC 
runs were performed.  If it is assumed that the heat generated during the polymerization 
reaction is directly proportional to the extent of the reaction (i.e. the reaction rate is 
proportional to the mole fraction of the unreacted liquid monomer), then the reaction rate 
constant (k) [in s-1], at a specified value of Td, can be calculated using:  
 
Equation 2.1               ( ) / ( )          [13]k H A B    
 
where H is the heat flow at temperature Td, A is the total area of the thermogram (the area 
of the thermogram between Ti and Tf), and B is the area of the thermogram between Ti 
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and Td.  The following Arrhenius equation was used with the fit of the k-Td results to 
calculate Q and ln Z:  
 
Equation 2.2              exp[ / ( )]          [13]dk Z Q RT  
 
where Z is the frequency factor (in s-1), Q is the activation energy (in J mol-1), and R is 
the molar gas constant (=8.314 J mol-1 K-1).  Six widely dispersed values of Td were 
selected from each thermogram.  For each cement, twelve values of Q and ln Z were 
obtained and means and standard deviations were calculated from each.  Each result was 
also compared to a control polymerization reaction rate value, k’, that was calculated at a 
physiologically relevant temperature of 37oC.  The k’ estimates were statistically 
analyzed using one-way or 2x2 factorial ANOVA for each of the individual parameters 
(COP, ACC, and accelerator).  For the interaction effect of COP and ACC, factorial 
ANOVA was used.  In all cases, p < 0.05 was taken as significant.  The maximum heat 
flow seen in the thermograms increased as the heating rates increases.  Figure 2.1 below 
shows typical thermograms obtained from the DSC tests.   
 
F igure 2.1  Typical thermograms obtained from the DSC tests [Reprinted from Journal of 
Biomedical Materials Research Part B: Applied Biomaterials, 81B, Gladius Lewis and Sanjay R. 
Mishra, Influence of Changes in the Composition of an Acrylic Bone Cement on its 
Polymerization Kinetics, Page 524, Copyright 2007, with permission from John Wiley and Sons]. 
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Section 2.2   Methods 
 
The following describes the study design for the first aim of this investigation.  The 
variables included type of bone cement, percentage of MWNTs added, and heating rate.  
Calculations were made to identify the activation energy, frequency factor, control 
polymerization reaction rate value, peak heat flow, and width at half maximum of peak 
heat flow.  MWNT loading ranged from 0.167wt% to 1.33wt%.  There were eight 
samples used in each experimental group.  These are the methods for the first aim of this 
research, to understand how MWNTs influence the polymerization kinetics of 
orthopaedic bone cement.   
 
Differential Scanning Calorimetry (DSC) is a thermoanalytical technique that measures 
the difference in the amount of heat required to increase the temperature of a sample in 
relation to a reference, measured as a function of temperature.  The sample and reference 
are placed in the DSC chamber where they then are subjected to the same temperature 
changes throughout the experiment.  A computer program is connected to the DSC that is 
used to design the experiment; the user can choose the temperatures and methods to test 
the sample.  The DSC can detect energy or heat capacity changes with great sensitivity.  
Typically the DSC is used to study phase transitions of a material, such as melting, glass 
transitions, or exothermic decompositions.  When a material or sample undergoes a phase 
transition, the amount of heat flowing to that sample will be different than a reference 
sample to maintain both at the same temperature.  For example, an exothermic process 
like bone cement polymerization requires less heat to raise the sample temperature.  An 
endothermic process like a liquid becoming a solid requires more heat.  While performing 
the experiment with the DSC, the computer program records the heat flow data and can 
output graphs of this information once the experiment is completed.  Typically these 
graphs, thermograms, show a curve of heat flux versus temperature or time.  A variety of 





Section 2.2.1   Polymerization Kinetics 
 
The current investigation began because the thermal benefits of MWNTs in bone cement 
had not been explored.  MWNTs (~25nm diameter; ~100µm length) were produced at the 
University of Kentucky Center for Applied Energy Research [55] and treated in a nitric 
acid bath to remove the residual catalyst particles [67].  Both a 0.25 and 1% mixture (by 
weight) of MWNTs were disaggregated and dispersed throughout dry pre-polymerized 
bone cement powder using a dual-blade shear mixer.  Thirty gram batches of hand-mixed 
powder were passed through the mixer three times, one minute each time, to ensure 
complete dispersion of the MWNTs in the bone cement powder.  The materials were 
mixed at room temperature and the MWNTs were not inserted into the polymer powder 
beads.  A method of mixing that included heating, cooling, and breaking down was used 
in previous studies completed by our lab [55].  This method results in the MWNTs being 
actually in the polymer beads.  The mixing method employed in the present investigation 
was simpler, quicker, and easier to make a variety of mixtures.  This may lower the 
effects that the MWNTs have on the polymerization kinetics of bone cement.   
 
Scanning electron micrographs (Figures 2.2 and 2.3) of a small representative sample of 
the resulting 1 wt% MWNT bone cement powder revealed the successful dispersion of 
MWNTs throughout the bone cement.  The larger globular shapes in Figure 2.3 are the 
barium sulphate molecules.  Visual observation can result in useful information regarding 
the spatial dispersion of multiwall carbon nanotubes in a polymer matrix [55].  Liquid 
monomer was prepared in the laboratory using 97.5% by volume methylmethacrylate 
(MMA) (ACROS Organics, Morris Plains, NJ) and 2.5% N,N-Dimethyl-p-toluidine 
(DMPT) (ACROS Organics, Morris Plains, NJ).  The DMPT acts as an accelerator and 





F igure 2.2  SEM image of the surfaces of Simplex bone cement polymer molecules with 
1 wt% MWNTs dispersed on the polymer particles. 
 
 
F igure 2.3  SEM Image of the MWNTs (finger-like shapes) covering the surface of one 




Cement samples were manually mixed in a ratio of 2 g of powder to 1 mL of as-noted 
monomer for 1 minute.  This diluted the concentration of MWNTs in the bone cement to 
0.17 wt% and 0.67wt%.  For each sample, approximately 26 mg of cement was quickly 
transferred to an aluminum sample pan, covered, pressed and then placed in a Q100 DSC 
(TA Instruments, New Castle, DE), operating under a nitrogen purge, with a constant 
flow rate of 100 cm3 min-1.  The specimen was heated from room temperature (Ti) to 
150oC (Tf) at one of three heating rates (5, 10, and 20oC min-1).  The exothermic heat 
flow (H) was recorded.  Thermograms were obtained for each cement formulation at each 
heating rate.  Triplicate experiments were conducted for combination of concentration 
and heating rate.      
 
The data from the thermograms was analyzed to calculate the parameters reaction rate, 
activation energy, and frequency factor.  First the heat flow data was shifted to start at 
zero and then the data was normalized with the mass of the corresponding sample.  The 
area under each data point, corresponding to one recorded time point (1 second), was 
calculated using the trapezoid rule.  The slope and y-intercept were then found for the 
normalized heat flow data versus time.  These values were used in the equation of a line 
to form a line connecting the end points of the data, shown in red in Figure 2.8.  The 
areas at each time point were better approximated using this line as the bottom limit 
instead of the horizontal axis.  The areas under each time point along this new line were 
calculated using the trapezoid rule as before.  This amount was then subtracted from the 
original area to have the best approximate area values.  The total area under the curve, A, 
down to that line and not the horizontal axis, was then found by adding all the small area 
values together.  This value was then compared with the original thermogram using the 
computer program Universal Analysis which is compatible with the original DSC data 




F igure 2.4  Example thermogram showing recorded heat flow data in blue and straight 
line used in accurately calculating area under the curve in red. 
 
Assuming first order polymerization kinetics [31], the reaction rate constant (k) of each 
thermogram was calculated at a selected temperature (Td) using Equation 2.1 from above.                                  
The activation energy, Q (J mol-1), and the frequency factor, Z (in s-1), were calculated by 
fitting the k and Td results to the Arrhenius Equation 2.2.  For each thermogram, several 
values of Td below the temperature corresponding to the peak heat flow were selected for 
analysis.  The heat flow value and corresponding values of A and B, were used to 
compute Q and ln Z.  The area under the curve was also calculated.  The area indicates 
the number of reactions that occurred during polymerization.  A control polymerization 
reaction rate value, k’, was also calculated for each sample.  This value was calculated 
using the equation for k above, using 37oC as the temperature, and the average Q and ln Z 
values for that sample set.  The Q, ln Z, area under curve, and k’ values were analyzed 
using 2-way ANOVA, comparing both influence of heating rate and MWNTs.   
 
Section 2.2.2   Isothermal Heating 
 
Polymerization kinetics can also be studied using an isothermal setting on a DSC [29].  
For these studies, instead of studying the polymerizing kinetics of bone cement while 





















37oC and held at that constant temperature for a specified amount of time.  This 
experimental method was used on two types of cement, Simplex (Stryker) and Palacos 
(Zimmer).  The measurements recorded by the DSC were used to further understand 
exactly how the cement polymerization occurs in the presence of both MWNTs and 
antibiotics.  The heat flow recorded by the DSC should rival the heat flow experienced by 
the tissues surrounding bone cement in an arthroplasty.  These experiments will be 
important in understanding heat flow in antibiotic loaded bone cement and if the addition 
of MWNTs can lower the peak temperatures experienced during polymerization without 
hindering the polymerization reactions.   
 
Section 2.2.3.1  Simplex Bone Cement   
 
Varying amounts, 0.25%, 1%, and 2% (by weight), of MWNTs produced at the Center 
for Applied Energy [55] were disaggregated and dispersed throughout dry pre-
polymerized Simplex bone cement powder using a dual-blade shear mixer.  Thirty-gram 
batches of hand-mixed powder were passed through this mixer three times to ensure 
complete dispersion of the MWNTs.  Liquid monomer was prepared according to 
standard commercial formulations, same as above in polymerization kinetics studies.  
The first set of isothermal studies investigated the affect of MWNTs on the 
polymerization of bone cement containing the antibiotic tobramycin.  For those samples, 
a clinically relevant (0.06 g, 3% by weight) dosage of tobramycin (X-Gen 
Pharmaceuticals, Big Flats, NY) was added to selected cement groups.  The antibiotic 
was added in powder form to the bone cement prior to the addition of the monomer.  It 
was hand mixed into the powder using a metal spatula. 
 
The second antibiotic studied was cefazolin.  This is a cephalosporin that has a lower 
denaturing temperature than some of the antibiotics more commonly used in arthroplasty.  
Completing isothermal DSC testing on bone cement samples with this antibiotic and 
MWNTs will help us to understand whether MWNTs lower peak polymerization 
temperatures enough to use a heat-labile antibiotic.  These antibiotics tend to be less 
expensive than the more commonly used gentamicin and tobramycin.   A clinically 
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relevant (0.05 g, 2.5% by weight) dosage of cefazolin (Novation, Irving, TX) was added 
to selected cement groups.  The same amounts of MWNTs, 0.25%, 1%, and 2% (by 
weight), produced at the Center for Applied Energy [55] were disaggregated and 
dispersed throughout dry pre-polymerized bone cement powder using a dual-blade shear 
mixer.  Thirty-gram batches of hand-mixed powder were passed through this mixer three 
times to ensure complete dispersion of the MWNTs.  Liquid monomer was prepared 
according to standard commercial formulations, same as above in polymerization kinetics 
studies.        
 
Components were manually mixed at room temperature for two minutes in the ratio of 2 
g of powder to 1 mL of monomer.  This diluted the concentration of MWNTs in the bone 
cement powders to 0.17 wt%, 0.67 wt%, and 1.34 wt%.  Approximately 20 mg of 
material was quickly transferred to an aluminum sample pan, covered, pressed, and then 
placed in a specimen container in the chamber of a differential scanning calorimeter 
(DSC).  The chamber was quickly heated to 37oC and maintained for 15 minutes.  The 
exothermic heat flow (thermogram) was recorded in triplicate for each MWNT and 
antibiotic loading.  Maximum heat flow (HFmax) and the width at half maximum heat 
flow (D) parameters were measured from these thermograms.  Mean values of HFmax and 
D were analyzed using a 2-way ANOVA.  
 
Section 2.2.3.2  Palacos Bone Cement 
 
Palacos R and Palacos bone cement that had been pre-mixed with the antibiotic 
gentamicin (Palacos+G) was studied using isothermal testing.  The samples with 
antibiotic contained approximately 0.025 g (1.25% by weight) of gentamicin that had 
already been mixed into the bone cement powder by the manufacturer.  MWNTs 
produced at the Center for Applied Energy [55] were disaggregated and dispersed 
throughout the dry pre-polymerized Palacos bone cement powder using a dual-blade 
shear mixer in varying amounts, first including 0.1%, 0.25%, 0.5%, and 1% (by weight).  
Mixtures were made from Palacos R and Palacos+G with each MWNT concentration, as 
well as control samples without MWNTs.  Twenty-gram batches of hand-mixed powder 
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were passed through this mixer three times to ensure complete dispersion of the MWNTs.  
Figure 2.5 (a,b) shows two SEM images of the Palacos powder that had been shear mixed 
with 1 wt% MWNTs.  Figure 2.6 (a,b,c) shows three SEM images of the Palacos+G 
powder that was shear mixed with 1 wt% MWNTs.  The images of the cement powders 
show that our method of mixing does not damage the polymer beads. 
 
(a)  
F igure 2.5  (a)  Palacos R polymer beads with visible zirconium dioxide 
molecules and (b)  Surface of one Palacos R polymer bead showing dispersion of 















F igure 2.6  (a)  Palacos+G polymer beads with visible zirconium dioxide 
molecules, (b)  Surface of one Palacos+G polymer bead showing dispersion of 






F igure 2.6  Continued 
 
The liquid monomer used was the commercially prepared ampule that came with the 
bone cement powder.  Components were manually mixed at room temperature for two 
minutes in the ratio of 2 g of powder to 1 mL of monomer.  This diluted the concentration 
of MWNTs to 0.067 wt%, 0.167 wt%, 0.33 wt%, and 0.67 wt% from 0.1%, 0.25%, 0.5%, 
and 1% (by weight), respectively.  After the cement components were mixed together for 
one minute, approximately 20 mg of material was quickly transferred to an aluminum 
sample pan, covered, pressed, and then placed in a specimen container in the chamber of 
a differential scanning calorimeter (DSC).  The chamber was quickly heated to 37oC and 
maintained for 15 minutes.  The exothermic heat flow (thermogram) was recorded in 
triplicate for each MWNT and antibiotic loading.  Maximum heat flow (HFmax) and the 
width at half maximum heat flow (D) parameters were measured from these 
thermograms.  Mean values of HFmax and D were analyzed using a 2-way ANOVA. 
 
Figure 2.7 displays SEM images of the 0.33wt% Palacos R and G composites.  Figure 2.7 
(a) shows the surface characteristics of a fractured Palacos R composite.  The porosity of 
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the material is evident.  Figure 2.7 (b) shows the polymer beads and interstitial regions 
after polymerization of the Palacos R sample.  Figure 2.7 (c) shows the surface of the 
Palacos G composite.  Figure 2.7 (d) shows the polymerization of the polymer beads with 
antibiotic and nanotubes in the Palacos+G composite.  It is evident that complete 
organized polymerization seen in bone cement with MWNTs does not occur.  Figure 2.8 
displays SEM images of the 0.67 wt% Palacos R composite.   
 
(a)  
F igure 2.7  (a) 0.33 wt% MWNT Palacos R composite surface, (b) 0.33 wt% MWNT 
Palacos R composite polymerization, (c) 0.33wt% MWNT Palacos+G composite surface, 










F igure 2.7  Continued 
 
 (a)  
F igure 2.8  (a),(b)  0.67 wt% MWNT Palacos R composite polymerization showing 





F igure 2.8  Continued 
 
 
The porosity of bone cement affects the mechanical properties of the material and 
therefore the replacement joint.  Pores prevent even dispersion of heat during polymer 
polymerization.  This indicates that the pores limit the complete result of adding MWNTs 
to bone cement powder to help systemize the polymerization process and reduce “hot 
spots”.  The amount of MWNTs added to the cement powder must be optimized to 
prevent too much porosity or the method of mixing the MWNTs into the powder needs to 
be improved.  Improving the mixing method, or possible using the more elaborate heating 
and cooling method, would limit the amount of porosity and therefore limit its negative 










Section 2.3   Results 
 
Section 2.3.1   Polymerization Kinetics Results 
 
These are results for the first aim of this research.  They explain how MWNTs influence 
the polymerization kinetics of orthopaedic bone cement when heated at a specific rate 
during the curing process.  Incorporation of MWNTs into Simplex bone cement powder 
was found to significantly affect the polymerization kinetics of the bone cement.  The 
thermograms collected from DSC showed that the MWNTs caused a dramatic drop in the 
peak heat flow and broadened the range of temperatures for all heating rates with both 
MWNT percentages (Figure 2.9).   
 
F igure 2.9  Thermogram trend for curing bone cement samples without MWNTs  

























F igure 2.10  Thermogram trend for curing bone cement samples with 0.17wt% MWNTs  
at the corresponding heating rates 
 
F igure 2.11  Thermogram trend for curing bone cement samples with 0.67wt% MWNTs  
























F igure 2.12  Average heat flow curves for curing pure and MWNT bone cements 
at the different heating rates 
 
A 2-way Anova analysis showed the frequency factor and control polymerization values 
were significant for the 0.17wt% samples.  The not significant combinations included the 
activation energy (Q) and the area under under the curve.  At heating rates of 5, 10, and 
20oC/min, the presence of MWNTs decreased the frequency factor of bone cement by 
10.8%, 3.1%, and 9.4%, respectively (Table 2.1).  The control polymerization values, k’, 
increased by 140.8%, 140.4%, and 55.4% at each of the 5, 10, and 20oC heating rates.  
The change in heating rate significantly affected the activation energy and frequency 
factor (both p values being less than 0.001).   
 
The 2-way Anova analysis for the 0.67wt% samples, at heating rates of 5, 10, and 
20oC/min, showed significance for the activation energy, frequency factor, area under the 
curve, and control polymerization values.  The presence of MWNTs decreased Q by 
32.8%, 28.7%, and 14.9% respectively (p<0.001) (Table 2.1).  Similarly, the 0.67wt% 



























34.4%, 30.8%, and 17.2%, respectively (p<0.001).  The area under the curves decreased 
by 28.8%, 31.7%, and 12.0%, respectively (p<0.001).  The control polymerization values, 
k’, increased by 21.4% and 19.9% at the 5 and 10oC heating rates.  The value decreased 
by 37% at the 20oC heating rate.  The k’ value is very sensitive to changes and could 
easily become an increased value if the sample size was increased.  A 1% change in one 
of the eight activation energy sample values resulted in a 12% change in k’.  The change 
in heating rate significantly affected the activation energy and frequency factor (both p 
values being less than 0.001). 
 
When both MWNT concentrations and the three heating rates were compared together, 
the influence of MWNT significantly affected the frequency factor (p=0.006) and the 
activation energy (p=0.008).  The increase in heating rate had a greater impact on the 
frequency factor (p<<0.001) and activation energy (p<<0.001) than the influence of 
MWNTs though. 
 
Table 2.1  Activation Energies, Frequency Factors, Areas,  
and Control Polymerization Values 












p   
value 
0% 
5 358.6 ± 80.6 133.1 ± 30.6 72.1 ± 3.6 0.002 --- 
10 253.3 ± 29.5 91.8 ± 12.0 61.2 ± 11.7 0.002 --- 
20 207.9 ± 11.3 73.0 ± 4.5 76.7 ± 10.5 0.000 --- 
0.17% 
5 319.0 ± 26.2 119.5 ± 9.3 60.2 ± 16.1 0.014 NS 
10 241.5 ± 71.2 89.0 ± 28.1 58.9 ± 12.7 0.009 NS 
20 189.5 ± 78.6 66.4 ± 28.9 69.7 ± 8.4 0.001 NS 
0.67% 
5 257.5 ± 9.4 94.1 ± 3.2 53.9 ± 8.2 0.003 < 0.001 
10 189.6 ± 22.8 67.3 ± 8.5 44.5 ± 13.7 0.002 < 0.001 








Section 2.3.3   Isothermal Heating Results 
 
Section 2.3.3.1  Simplex Results 
 
These are results for the first aim of this research.  They explain how MWNTs influence 
the polymerization kinetics of orthopaedic bone cement during curing at a constant 
temperature.  Thermograms collected from DSC showed that the MWNTs and the 
antibiotic tobramycin decreased the maximum heat flow (HFmax) and increased the full 
width at half maximum heat flow values (D) (Table 2.2).  Figure 2.13 shows the 
influence of MWNT addition alone on the thermograms collected during isothermal 
testing.  Figure 2.14 shows the influence of both MWNT and tobramycin addition.   
 




























F igure 2.14  Selected heat flow curves for pure, MWNT loaded, and antibiotic  
loaded bone cement 
 
Table 2.2  Maximum Heat Flow and Duration for MWNT and  
Tobramycin Loaded Simplex Bone Cement 








0% 0 1.30±0.11 0.87±0.22 0.06 0.85±0.05 1.45±0.31 
0.17% 0 0.99±0.22 1.27±0.18 0.06 0.63±0.14 1.84±0.42 
0.67% 0 0.48±0.08 2.17±0.20 0.06 0.35±0.08 3.10±0.75 
1.34% 0 0.20±0.02 4.90±0.56 0.06 0.20±0.04 5.55±1.21 
 
MWNTs were associated with a 25-85% reduction in HFmax and a 45-460% increase in D 
(p<0.001).  Tobramycin addition alone was associated with a 35% reduction in HFmax and 
a 70% increase in D (p<0.001).  The interaction between the heat flow reduction caused 
by both MWNTs and antibiotic was significant with a 50-85% reduction in HFmax and a 





























To ensure that the decrease in peak heat flow and increase of width at half maximum in 
the samples with both MWNTs and antibiotic was not from antibiotic alone, the 
tobramycin was tested in the DSC alone.  The antibiotic and monomer were mixed in the 
same ratio as in the cement samples and placed in the DSC at 37oC for 15 minutes.  The 
experiment was run in triplicate and the thermograms averaged.  These thermograms 
were then subtracted from the original cement sample data with MWNTs but without 
antibiotic to see if the results would be the same.  Those quantitative results showed that 
the antibiotic alone would decrease the peak heat flow by 3-25% (p<0.001) and increase 
the width at half maximum by up to 50% (p<0.001).  The differences seen were still 
significant numerically but the combination of the antibiotic into the MWNT cement 
mixture prior to heating in the DSC shows a greater drop in peak heat flow and increase 
in width at half maximum.  The combination of the MWNTs and the antibiotic must work 
together to impact the thermal properties of the polymerizing bone cement.  Figure 2.15 
compares the applications of antibiotic.  Visually it is easy to identify that the samples 
with the tobramycin mixed in prior to heating reduced the peak heat flow more 





F igure 2.15  Comparison of cement samples with tobramycin actually in samples 
(MWNT with tobra) and the quantitative effects found by combining the tobramycin and 
MWNT cement results (MWNT –tobra). 
 
Thermograms collected from DSC showed that the MWNTs and the antibiotic cefazolin 
decreased the maximum heat flow (HFmax) and decreased the full width at half maximum 
heat flow values (D) (Table 2.3).  Figure 2.16 shows the influence of MWNT and the 




































F igure 2.16  Selected heat flow curves for pure, MWNT loaded, and cefazolin  
loaded bone cement 
 
Cefazolin addition without MWNTs was associated with a 32% reduction in HFmax and a 
85% decrease in D (p<0.001) (Table 2.3).  The interaction between the heat flow 
reduction caused by both MWNTs and antibiotic was significant with a 20-75% reduction 
in HFmax and a 85-90% decrease in D (p<0.001) (Table 2.3).  MWNTs in bone cement 
augmented with cefazolin were associated with decreases in peak height and width at half 





































Table 2.3  Maximum Heat Flow and Duration for MWNT and  
Cefazolin Loaded Simplex Bone Cement 








0% 0 1.30±0.11 0.87±0.22 0.05 0.88±0.14 0.13±0.08 
0.17% 0 0.99±0.22 1.27±0.18 0.05 1.04±0.08 0.10±0.02 
0.67% 0 0.48±0.08 2.17±0.20 0.05 0.80±0.11 0.13±0.01 
1.34% 0 0.20±0.02 4.90±0.56 0.06 0.34±0.02 0.11±0.02 
 
In the experiments using tobramycin as the antibiotic, the width at half maximum values 
increased as the percentage of MWNTs included increased.  The opposite effect was seen 
with the cefazolin antibiotic.  In those samples, the width at half maximum values 
decreased as the percentage of MWNTs included increased.  The widths at half maximum 
values were used as a way to help quantify polymerization of the material.  It was 
hypothesized that the presence of MWNTs would decrease the peak polymerization 
temperatures reached and increase the time of polymerization to achieve complete 
polymerization.  This result was seen in the individual isothermal studies just looking at 
the addition of MWNTs as well as in the studies with the presence of the antibiotic 
tobramycin.  The peak heat flow values recorded decreased with the addition of MWNTs 
but in order for complete polymerization of the monomer, the duration of polymerization 
increased.  Graphically this can be examined by looking at the area under the 
thermograms.  In the cefazolin cases, the polymerization duration appears to be 
decreasing.  This would indicate that complete polymerization is not occurring in these 
samples.  Figure 2.17 below compares the influence of MWNT and both antibiotic 
additions.  In this figure you can examine the thermogram peaks and widths among all 






F igure 2.17  Selected heat flow curves for pure, MWNT loaded, tobramycin, and 
cefazolin loaded bone cement 
 
Section 2.3.3.2  Palacos Results 
 
Thermograms collected from DSC showed that the MWNTs decreased the maximum 
heat flow (HFmax) and increased the full width at half maximum heat flow values (D) but 
in a different way than in the Simplex cement (Table 2.4).  Figure 2.18 shows the 
influence of MWNT addition on the Palacos R and Palacos+G thermograms collected 




































F igure 2.18  Selected heat flow curves for pure, MWNT loaded, and gentamicin loaded 
Palacos bone cement 
 
MWNTs were only associated with one significant reduction in HFmax and increase in D, 
and that was in the 0.33 wt% samples (75% decrease and 235% increase, respectfully, 
p<<0.001 ).  The 0.067 wt% and 0.167 wt% samples had no significant reduction in peak 
heat flow or width at half maximum as a result of MWNT addition.  There was no 
measurable peak in the 0.67 wt% samples.  The pure Palacos+G samples with no 
MWNTs had an average reduction in peak height reduction of 25% and an average 
increase in width at half peak of 15% (p<<0.001).  Similar curves were seen in the 
Palacos+G samples with the addition of MWNTs.  Only the 0.33 wt% samples had 
significant changes in measured variables.  HFmax decreased by 88% and D increased by 
300% in those samples (p<<0.001 ).  The antibiotic alone only significantly affected the 
width at half peak in the samples 0.67 wt% samples (p=0.01).  The heat flow reduction 
































Table 2.4  Maximum Heat Flow and Duration for MWNT and  
Gentamicin Loaded Palacos Bone Cement 








0% 0 0.91±0.17 1.52±0.20 0.025 1.15±0.01 1.28±0.06 
0.067% 0 1.13±0.09 1.24±0.14 0.025 1.09±0.29 0.83±0.66 
0.167% 0 1.01±0.03 1.36±0.17 0.025 1.36±0.09 1.06±0.12 
0.33% 0 0.22±0.07 5.09±0.42 0.025 0.11±0.04 6.21±0.50 
 
Since there was no measurable peak in the 0.67 wt% samples, it was assumed that 
polymerization of the bone cement did not occur in those samples.  The temperature of 
the samples did not rise like the other samples.  The MWNTs prevented the 
polymerization reaction from occur in both the samples with and without antibiotic.  
From this point forward, only percentages of MWNTs less than 0.67 wt% were used in 
testing with Palacos R and Palacos+G cement. 
 
After completing the isotherm polymerization studies with Palacos R and Palacos+G, it 
was recognized that the polymerization kinetics of Simplex and Palacos cements were 
different.  When comparing the effects of different percentages of nanotubes, significant 
differences between the two types of cement were found.  The isotherm study of Palacos 
was expanded to include other weight percentages of MWNTs to try to identify where the 
cut-off point for complete polymerization was.  It was already known that 0.67 wt% 
MWNTs did not allow polymerization to occur.  Intermediate percentages including 
0.302 wt%, 0.268 wt%, and 0.201 wt% were investigated.  Figure 2.19 shows the 





F igure 2.19  Selected heat flow curves for a variety of MWNT loadings in  
Palacos bone cement 
 
MWNTs were only associated with significant reductions in HFmax and increases in D in 
the samples with percentages of MWNTs greater than 0.201 wt% (25-75% decrease and 
1-235% increase, p<<0.001 ).  Table 2.5 shows the average heat flow maximum and 
width at half maximum values for all the MWNT Palacos samples.   
 
Table 2.5  Maximum Heat Flow and Duration for all  
MWNT Palacos Bone Cement Samples 






0% 0.91±0.17 1.52±0.19 
0.067% 1.13±0.09 1.24±0.14 
0.167% 1.01±0.03 1.36±0.17 
0.201% 0.98±0.18 1.37±0.30 
0.268% 0.94±0.07 1.53±0.23 
0.302% 0.69±0.10 1.65±0.04 




























The first MWNT percentage that significantly decreased peak heat flow was 0.268 wt%. 
Only increasing the MWNT percentage by 0.05 wt% decreased the average heat flow by 
25%.  This indicates that the range of 0.4-0.45 wt% MWNTs is where MWNTs decrease 
peak heat flow but still allows polymerization to occur.  Once the percentage of MWNTs 
is again raised by 0.05 wt%, the average peak heat flow values decrease an additional 
50%.  The width at half maximum at this point is also significantly increased (235%) but 
complete polymerization of the material may not be occurring.  The Palacos cement 
appears to be much more susceptible to the MWNTs changing its polymerization than the 
Simplex cement. 
 
Section 2.3.3.3  Comparison of Simplex and Palacos Bone Cement 
 
MWNTs influenced the polymerization kinetics of the two cement brands differently.  
Graphical analysis was completed on the average thermograms for both types of cements 
shown in Figure 2.20.  The differences between the peaks of the thermograms with 





F igure 2.20  Selected thermograms for Palacos and Simplex bone cements 
 
Comparing, HFmax and D from the previous isothermal experiments shows the peak heat 
flow values between the two pure cements with MWNTs has an average difference of 
26% (p=0.03).  The Palacos cement had lower heat flow values when compared to the 
Simplex cement.  The pure Palacos samples also had an average width at half maximum 
that was 46% larger (p=0.03) than the Simplex samples.  The other samples that could be 
directly compared were the 0.167 wt% MWNT samples.  The variable differences in 
these samples were smaller.  Palacos had a peak heat flow that was on average 5% lower 
than Simplex, and a width at half peak that was on average 6% wider (p>0.05).  As the 
percentages of added MWNTs increased, the differences in peak height also increased.  
In the 0.67wt% case, the Simplex samples still have a visible positive peak heat flow 
while the Palacos samples have an almost horizontal line below the positive horizontal 
axis.  The difference in average HFmax was that the Palacos values were 230% lower than 









































not calculated due to the lack of a real peak.  Table 2.6 displays the peak heat flow values 
and width at half maximum values for all the samples in the figure.   
 
Table 2.6  Heat Flow Maximum and Duration Comparison for  
Palacos and Simplex Bone Cement  
(N/D means No Data and N/M means Not Measured) 








0% Palacos 0.99±0.12 1.41±0.16 Simplex 1.30±0.11 0.87±0.22 
0.167% Palacos 1.01±0.03 1.36±0.17 Simplex 1.06±0.10 1.27±0.18 
0.268% Palacos 0.94±0.07 1.53±0.23 Simplex N/D N/D 
0.302% Palacos 0.69±0.10 1.65±0.04 Simplex N/D N/D 
0.33% Palacos 0.22±0.07 5.09±0.42 Simplex N/D N/D 
0.67% Palacos -0.01±0.01 N/M Simplex 0.48±0.08 2.17±0.20 
1.34% Palacos N/M N/M Simplex 0.20±0.02 4.90±0.56 
 
 Visually and numerically it can be seen that the Palacos 0.33 wt% MWNT samples had 
very similar thermograms to the Simplex 1.34 wt% MWNT samples.  The polymerization 
of the Palacos samples began about 45 seconds after the Simplex samples.  This is one of 
the differences between the MWNT effects on the polymerization of the different 
commercial bone cement powders.   It is interesting to see how a small percentage of 
MWNTs inhibits polymerization in the Palacos cement.  The polymerization in these 
samples may occur over a longer period of time but all of our experiments were limited to 








Section 2.4   Discussion  
 
Section 2.4.1   Polymerization Kinetics Conclusions 
 
Multiwall carbon nanotubes influence the polymerization characteristics of bone cement.  
MWNTs significantly and positively affected the thermal properties of Simplex bone 
cement.  They increased the time required to completely polymerize the 
methylmethacrylate monomer which adds time for the surgeon to position the implant.  
More importantly, they decreased the rate of heat release, shown by decreases in 
activation energy and frequency factor, and this will likely contribute to a decrease in the 
peak exothermic temperature of the bone cement.  Reducing the temperature of the in situ 
polymerizing cement means that there is less likelihood of thermal necrosis and, 
therefore, a more biologically viable bone cement-bone interface will result.  This will 
positively affect the mechanical integrity of the interface and improve implant longevity.  
The addition of MWNTs to bone cement may help avoid polymerization induced “hot” 
spots.  MWNTs can also be used to distribute heat from the cement mantle that can be the 
cause of hyperthermia-based destruction of adjacent bone by conducting the heat to the 
metal in the implant.   
 
The carbon nanotubes must be inhibiting some of the polymerization reaction.  The areas 
under the curve were similar in all samples with the same MWNT percentage, even with 
the different heating rates.  But the areas under the curve did decrease with the addition 
of MWNTs.  The areas relate to the total energy in the system in relation to the heating 
rate, or the number of reactions that occurred during polymerization.  If the areas are 
roughly the same, the same degree of polymerization has occurred.  The addition of 
carbon nanotubes caused a signficant decrease in thermogram area.  The polymer part of 
the reaction cannot be controlled as easily as the kinetics reaction.   
 
It has been suggested that a low k’ indicates a higher degree of conversion of the liquid 
monomer, which may lead to a smaller amount of residual monomer, contributing to 
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long-term in vivo stability of the replacement [11].  The k’ values of the samples with 
MWNTs significantly increased when compared to the control samples.  This indicates 
that the amount of residual monomer is actually increasing, there is a lower degree of 
monomer conversion in the MWNT samples.  The addition of MWNTs to the bone 
cement powder is likely preventing all of the polymerization reactions from occurring.  
The MWNTs may be getting in the way of some of the free radical reactions by either 
physically being in the way or actually chemically binding to some of the free radicals 
themselves.  To have more complete polymerization of the bone cement material, the 
percentage of MWNTs added to the mixture must be minimal.  If the percentage of 
MWNTs is too large, where near complete polymerization does not occur, not only will 
the thermal properties be affected but the mechanical properties as well.  The strength of 
bone cement is dependent on the polymerization reactions.  If enough polymerization 
reactions do not occur, the material does not harden, and could not be used in orthopaedic 
surgery like it is today.  An optimal balance of MWNT weight percent must be found 
through future studies.  This optimal range should have the increase in mechanical 
properties due to the MWNTs presence accounting for the subsequent decrease in 
polymerization reactions which decreases the mechanical properties.  A limitation of 
these studies is the inability to know how many polymerization reactions are occurring.  
If this was better understood it would be easier to identify the optimal percentages of 
MWNTs to ensure the best performance material.   
 
The high exothermic temperatures of bone cement polymerization also limit the 
therapeutic potency of the antibiotics used in arthroplasty.  Antibiotics that are not heat 
labile denature at temperatures above 100oF.  Despite contemporary efforts to minimize 
contamination, infection remains a significant concern in all arthroplasty procedures.  
Antibiotics are denatured at certain temperatures, a temperature which can be reached 
during cement polymerization.  Presently there are less expensive antibiotics that would 
positively prevent orthopaedic infections, but these antibiotics denature at temperatures 
exceeded during polymerization.  Lowering the polymerization temperature to below 
100oF would increase the choice of antibiotics available to the patient and the surgeon.  If 
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the lowered temperature could be achieved without diminishing antibiotic potency, it 
would also positively affect the mechanical integrity of the interface and would greatly 
improve implant longevity.     
 
Section 2.4.2   Isothermal Heating Conclusions 
 
MWNTs were shown to substantially alter the flow of heat liberated during the 
polymerization of both Simplex and Palacos bone cement.  The benefits of this include: 
1) new options for use of heat-labile antibiotics in TJA, 2) improved antibiotic potency, 
3) fewer “hot spots” that can nucleate fatigue cracks, 4) greater biological viability of the 
bone-bone cement interface, and 5) mechanical strengthening of the matrix otherwise 
weakened by antibiotic incorporation.  These benefits support our belief that MWNTs in 
antibiotic laden bone cement can result in enhanced clinical performance of cemented 
total joint implants.   
 
The polymerization of Palacos cement is more affected by the presence of MWNTs than 
Simplex cement because of its viscosity and molecular weight differences.  Palacos is 
sterilized by ethylene oxide and is a high molecular weight cement.  Simplex is sterilized 
by γ-irradiation and is a low molecular weight cement [4].  Palacos powder has a 
measured molecular weight of approximately 950 kDa and Simplex powder has 
molecular weight estimated at 100 kDa [76].  Palacos being a high viscosity cement plus 
the addition of MWNTs may make the mixture too viscous.  If the viscosity is too high, 
the free radicals cannot find the double bonds and polymerization will not occur.  The 
lower viscosity, Simplex cement, cures to a much greater extent with MWNTs.  
Questions arise as a way to possibly alter this result and allow the higher viscosity 
cements like Palacos to polymerize better with the presence of MWNTs.  Adding more 
BPO could limit the negative effects of MWNT presence, but this raises the issue of how 
would this change the mechanical properties of the material.  Concerns exist that 
MWNTs are getting in the way or attaching to the free-radicals themselves; thus 
preventing the joining with the double bonds and polymerization.  Currently the reactions 
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occur in a more localized way, sporadically throughout the sample.  This leads to hotter 
regions in the material that cause the polymerization heat spike.  If the reactions could be 
more systemic, the polymerization reactions would be more gradual and the maximum 
temperatures reached could be minimized.  Also, we want to see optimization among the 
maximum temperature reached during polymerization, mechanical properties, and elution 
properties.  The MWNT percentage that provides the best result in each of those cases 
needs to be identified.  This percentage should decrease peak heat flow, increase 
polymerization time, and increase mechanical stability.  These studies could also have 
been expanded by finding a direct calculation to go from the measured heat flow to 
temperature in the polymerizing material.  It would be easier to understand the affects of 
MWNTs on bone cement polymerization and the nature of what would occur when the 




Chapter 3 - E lution Properties of Antibiotic Bone Cement with  
Multiwall Carbon Nanotubes 
 
Section 3.1   Background  
 
The use of bone cement as a source of antibiotics has been around for almost forty years.  
Methylmethacrylate is clearly capable of serving as a route of administration for 
antibiotics.  PMMA appears to be an adaptable material that can be manipulated to 
modify the antibiotic elution profile to match a given clinical situation [77].   
Controversies do exist over the best use of different antibiotics, cements, and their 
combinations.  It is not yet known how to provide the best antibiotic to patients who have 
different requirements with the antibiotic-cement combination to meet their needs.  
Antibiotics in bone cement leach out of the hardened plastic material by diffusion.  The 
idea is that the antibiotics are released from the cement gradually over time in such a way 
that the local levels of antibiotics exceed the minimal inhibitory concentration of the 
pathogen [78].  The amount has been found to be proportional to the surface area of the 
cement [35].  It is quite obvious from elution kinetics that not every bone cement or 
antibiotic is suitable for use in an antibiotic bone cement mixture for arthroplasty.   
The potential benefits of antibiotic-loaded cement outweigh its potential risks [79].   
 
Antibiotic-loaded cement is used in two ways.  One way is to treat infection, using 1- 3.6 
g of antibiotic per 40 g of acrylic cement to have effective elution kinetics and sustained 
therapeutic levels of antibiotic [80].  Higher doses, between 6 and 8 g of antibiotic per 40 
g of bone cement, can be used in cement beads or spacers [81].  Not all the bone cement 
is used in every case, but the whole 40 g of bone cement is mixed with the antibiotic to 
maintain the correct ratio.  The packets of bone cement come premeasured from the 
cement manufacture.  The second way antibiotic-loaded cement is used is as prophylaxis.  
This requires low doses of antibiotics in the bone cement to avoid adverse mechanical 
effects because of the use of this cement as mechanical fixation for an implant [82].  
Low-dose antibiotic-loaded bone cement (ALBC) is typically defined as ≤ 1 g of 
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powdered antibiotic per 40 g of bone cement.  Figure 3.1 is a flowchart created by Jiranek 
et al that outlines the different uses of antibiotic-loaded bone cement [82].  Continuous 
use of the same antibiotics develops the potential for creating drug resistant bacteria that 
are resistant to this type of treatment. 
 
 
F igure 3.1  Guidelines for clinical use of antibiotic-loaded bone cement.  *Antibiotics 
recommended for prophylaxis include gentamicin or tobramycin.  **The antibiotic(s) 
used depends on the susceptibility of the microorganisms identified or suspected [82]. 
 
The United States Food and Drug Administration (FDA) approved the use of antibiotic-
impregnated bone cement products for prosthetic fixation after eradication of a previous 
infection.  The commercially available materials only contain a low-dose of antibiotics.  
Bone cement beads and spacers used to treat established infections typically use a higher 
dose of antibiotics to achieve desired elution and sustained therapeutic levels.  Using 
high-dose antibiotic loaded cement requires the orthopaedic surgeon to hand-mix the 
appropriate agents as needed [83].  Table 3.1 displays the current FDA approved 





Table 3.1  Food and Drug Administration-Approved Premixed  
Antibiotic Bone Cements Used in Study [14] 
Product Distributor V iscosity Antibiotic (Amount) 
Cemex Genta Exactech Low Gentamicin (1.0 g) 
Cobalt G-HV Biomet High Gentamicin (0.5 g) 
Palacos R + G Zimmer High Gentamicin (0.5 g) 
Simplex P Stryker Medium Tobramycin (1.0 g) 
Smartset GHV DePuy High Gentamicin (1.0 g) 
 
There are conflicting reports discussing the mechanism by which antibiotics are released 
from bone cement, including looking at whether they can diffuse through the cement or 
are removed only from its surface [42].  It is known that there are many factors that affect 
elution profiles, including the type of cement used, the choice of antibiotic, and the 
preparation method.  Antibiotic release must be dependent on factors including its 
molecular weight, the molecular weight and degree of cross-linking of the polymer , the 
solubility of the drug in the polymer, and the relative solubility of the drug in the polymer 
and in the medium outside the matrix [42].  The mechanical properties of the cement are 
also important and choices about antibiotic loading must be made based on the need for 
the cement.  Porosity is also important in elution.  When porosity is created by materials 
in the cement, elution is improved, but too much porosity can compromise desired 
mechanical properties as much as 30-50% [22].  But the compressive strength of PMMA 
is many times greater than required in the clinical setting and even a 45% decrease would 
not compromise its function as a spacer [83].   
 
It was also proposed that antibiotic elution may change if more than one antibiotic is 
introduced into the cement.  The idea that the addition of a second antibiotic improves 
antibiotic elution has been termed the synergistic effect.  Initially it seems that the elution 
is strongly affected by the amount of antibiotic that is on the surface of the test sample.  
Once that antibiotic is eluted, the presence of the second antibiotic may facilitate the 
elution of the first antibiotic from open cavities within the cement.  It is believed that the 
synergistic effect is due to the increased porosity of the cement caused by the elution of 
antibiotic molecules, therefore improving the overall elution rate [84].  Masri et al termed 
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the phenomenon the process of “passive opportunism of antibiotic elution from bone-
cement” [84].   
 
It has been generally accepted that Palacos R (Smith & Nephew Orthopaedics, Memphis, 
TN) has superior elution characteristics compared with other cement types [79].  
Maximizing the efficiency of antibiotic release may improve therapeutic efficacy and 
cost efficiency [85].  Maximizing antibiotic release from cement may offer clinical 
benefit and at least may offer theoretical advantages, such as decreased development of 
antibiotic resistance, improved treatment efficacy, and increased cost efficiency.  If these 
benefits can be obtained without an increase in cost or risk to the patient, choosing the 
cement with the maximal elution rate seems warranted.   
 
Being able to find a way to use liquid gentamicin instead of the costlier powdered 
antibiotics would be a significant way to decrease related costs.  Currently, tobramycin is 
widely used in the US but it is very expensive ($120 per 1.2 g dose [83]) and has been in 
short supply.  Gentamicin has been used to treat musculoskeletal infections for years but 
is as expensive as tobramycin when in its powdered form, and is unavailable in some 
countries.  Liquid gentamicin is much cheaper ($4 per 480 mg dose [83]), is readily 
available, and is one of the most commonly used agents in clinical settings.  If 
tobramycin in bone cement spacers could be replaced with liquid gentamicin, it was 
estimated that an annual antibiotic cost savings of $7,400,000 could be achieved in the 
US for total joint implant infections treatment [22].   
 
Hsieh investigated the use of liquid gentamicin in combination with vancomycin [83].  It 
is known that using liquid antibiotic in bone cement for the implantation of prosthesis is 
unsuccessful because the cement has inferior mechanical properties.  But because 
antibiotic-impregnated beads or spacers are only temporary, the mechanical properties 
are not as important.  During a five week study period, vancomycin elution was enhanced 
by 146% with the addition of gentamicin liquid and gentamicin elution was enhanced by 
45% with the addition of vancomycin.  The liquid gentamicin also significantly increased 
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the porosity of the specimens, both with and without vancomycin.  Ultimate compressive 
strength was reduced by 13%, 37%, and 45% in samples with vancomycin alone, 
gentamicin liquid alone, and vancomycin with liquid gentamicin, respectively [83].   
 
One of problems with antibiotic loaded bone cement is that the antibiotics elute very 
quickly out of the cement, into the blood stream, and away from the intended site of 
action.  If the elution time could be extended, the “dwell time” of the antibiotic could be 
extended, thereby rendering the antibiotic more effective against existing or potential 
infection.  Most of the antibiotic that is added to the cement also becomes trapped in the 
polymer matrix and is never able to elute into the surrounding system.  The antibiotic that 
is eluted typically comes from the exterior of the bone cement.   
 
Carbon nanotubes are now being considered for drug delivery.  They can be implanted at 
sites where a drug is needed without trauma, and slowly release the drug over time [86].  
Carbon nanotubes could also potentially be used as part of the antibiotic bone cement 
drug delivering system.  Their presence in the bone cement matrix could assist the 
antibiotic in getting out of the center of the bone cement.  The purpose of this specific 
study was to determine if MWNTs affect the elution rate of antibiotics or improve the 
amount of antibiotic eluted out of bone cement. 
 
Section 3.2   Methods 
 
The following describes the study design for the second aim of this investigation.  The 
variables included percentage of MWNTs added and elution sampling time.  Calculations 
were made to identify the total antibiotic elution and the elution rate throughout the 
study.  MWNT loading ranged from 0.33wt% to 1.34wt%.  There were eight samples 
used in each experimental group.  These are the methods for the second aim of this 
research, understanding how MWNTs influence the elution of antibiotics from 




After performing an extensive literature search, a pilot elution study was developed.  
Palacos bone cement (Zimmer, Warsaw, IN) both with and without the premixed 
antibiotic gentamicin (Palacos+G) was used to create MWNT mixtures.  MWNTs 
produced at the Center for Applied Energy [55] were disaggregated and dispersed 
throughout the dry pre-polymerized Palacos bone cement powder using a dual-blade 
shear mixer.  Mixtures were made with Palacos and Palacos+G for each MWNT 
concentration, as well as control samples without MWNTs.  This resulted in 4 mixtures 
with antibiotic and 4 mixtures without antibiotic.  Three of the mixtures in each group 
contained MWNTs.  Commercial formulations with 40 g of sterile bone cement powder 
were used to create the mixtures.  The Palacos+G formulation contained approximately 
0.5 grams of gentamicin (1.25 wt%) per box.  Forty-gram batches of hand-mixed powder 
were passed through the shear mixer three times to ensure complete dispersion of the 
MWNTs.  The liquid monomer used was the commercially prepared ampule that came 
with the bone cement powder.  Components were manually mixed at room temperature 
for two minutes in the ratio of 40 g of powder to 20 mL of monomer.  The MWNT 
mixtures had percentages of 0.33%, 0.67%, and 1.34% (by weight).  Figure 3.2 (a,b) 
displays SEM images of one of the 0.33 wt% MWNT Palacos R composites with liquid 
gentamicin.  Figure 3.2 (a) shows the immense porosity in the cement sample with liquid 
antibiotic and Figure 3.2 (b) shows the alteration of polymer molecules during 






F igure 3.2 (a) Surface characteristics of 0.33 wt% MWNT Palacos R and liquid 
gentamicin composite and (b) Altered polymerization of 0.33 wt% MWNT Palacos R 
and liquid gentamicin composite. 
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After mixing the components manually until the cement had reached the doughy phase, 
the material was manually pressed into an acrylic mold that produced 6 mm diameter 
spherical shaped specimens.  Five specimens were formed for each of the test groups.  
They were allowed to cure for one hour at room temperature.  The specimens were then 
weighed individually.  Each specimen was immersed in a plastic test tube containing 30 
mL of PBS and kept at room temperature until the designated sampling times.  At each 
sampling time, the tubes were slowly shaken three times and then 0.5 mL of the PBS 
solution was removed and stored at -20oC until analysis.  No new PBS was added to the 
tubes.  Samples were taken at 1, 3, 6, and 24 hours.  This method was adapted from an 
extensive literature search that covered current methods used in antibiotic bone cement 
studies.  Most current literature measures antibiotic concentration in the samples using 
fluorescence polarization immunoassay (FPIA).  We did not have the capability to use 
this technique but were able to use particle-enhanced turbidimetric inhibition 
immunoassay (PETINIA) instead.  This method is a precise and accurate alternative to 
FPIA [87].  The assay has a range of 0.5-12.0 µg/mL.  The antibiotic concentration 
results were multiplied by the total concentration of PBS in the test tube to calculate total 
antibiotic release per bead at each sample interval.  This value was then divided by the 
elution time for the given interval to get an elution rate in µg/hour for each bead.   
 
Section 3.3   Results 
 
These are the results for the second aim of this research.  They explain how MWNTs 
influence the elution of the antibiotic gentamicin from spherical samples of orthopaedic 
bone cement.  Gentamicin was released from bone cement with and without MWNTs 
(Figure 3.3 and 3.4).  The elution occurred mainly in the first few hours, 66-86% of total 
antibiotic was eluted during the first three hours.  The addition of MWNTs did increase 
the amount of antibiotic released and the elution rate in all of the cases except for the 
0.67wt%.  The initial gentamicin elution after 1 hour was increased by 9% with the 
addition of 0.33 wt% MWNTs and increased by 25% with the addition of 1.34 wt% 
MWNTs.  The concentration with 0.67% MWNTs by weight decreased the amount of 
initial antibiotic elution by 27%.  The total gentamicin elution after 24 hours was 
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increased by 32% with the addition of 0.33 wt% MWNTs and increased by 23% with the 
addition of 1.34 wt% MWNTs.  The concentration with 0.67% MWNTs by weight 
decreased the amount of initial antibiotic elution by 35%.  The initial elution rate was 
also increased in the 0.33 wt% and 1.34 wt% samples (by 9 and 25%, respectively).  The 
initial elution rate decreased by 27% in the 0.67 wt% MWNT samples.  The final elution 
rate increased in the 0.33 wt% and 1.34 wt% samples (by 32 and 23%, respectively).  The 
final elution rate decreased by 35% in the 0.67 wt% MWNT samples.  Table 3.2 shows 
the average elution amounts and elution rates for each sample type and time.  Figure 3.3 
displays the total accumulated gentamicin elution amount per bead per sampling time and 
Figure 3.4 displays the elution rate per sample type and time.  Due to time and budget 
constraints, this study was only completed one time.   Only one batch of 40 mg cement 
was mixed and used in this run.  A replicate study and modified studies are outlined as 
future work for this project.  
 
Table 3.2  Elution Amounts and Rates for Each Sample 
M W N T Percentage 
(wt%) 
Sampling T ime 
(hr) 
Total E lution Amount 
(µg) 
E lution Rate 
(µg/hr) 
0 
1 61.95 61.95 
3 75.4 25.13 
6 79.8 13.3 
24 95.2 3.97 
0.33 
1 67.85 67.85 
3 87 29 
6 102.6 17.1 
24 131.6 5.48 
0.67 
1 47.2 47.2 
3 58 19.33 
6 62.7 10.45 
24 67.2 2.8 
1.34 
1 79.65 79.65 
3 95.7 31.9 
6 102.6 17.1 





F igure 3.3  Accumulated gentamicin elution per sampling time for 
each MWNT concentration. 
 















































































After completing the pilot study it was determined that the optimal MWNT percentage to 
use in the expanded elution study was 0.33 wt%.  This concentration had the highest 
amount of gentamicin eluted from the sample after 24 hours.  The hypothesis of the 
complete elution study is that the addition of MWNTs to bone cement will increase the 
total antibiotic elution amount and decrease the elution rate so that antibiotic is eluted for 
a longer period of time when compared to pure bone cement without MWNTs.  The 
complete elution study protocol included using a MWNT concentration of 0.33 wt% and 
two forms of gentamicin, the powdered, pre-mixed form in Palacos+G and liquid 
gentamicin that would be added to Palacos.  In both cases controls were made without 
nanotubes.  MWNTs produced at the Center for Applied Energy [55] were disaggregated 
and dispersed throughout the dry pre-polymerized Palacos bone cement powder using a 
dual-blade shear mixer.  This resulted in 6 mixtures, a) pure Palacos, b) pure Palacos with 
0.33 wt% MWNTs, c) pure Palacos+G, d) pure Palacos+G with 0.33 wt% MWNTs, e) 
pure Palacos with liquid gentamicin, and f) pure Palacos with liquid gentamicin and 0.33 
wt% MWNTs.  One commercial formulation of 40 g of sterile bone cement powder was 
used in each of the six mixtures.  The Palacos+G formulation contains approximately 0.5 
grams of gentamicin (1.25 wt%) per box.  The equivalent amount of liquid gentamicin 
was used in the Palacos samples.  The small batch size was one of the biggest limitations 
of this study. 
 
Forty-gram batches of hand-mixed powder were passed through the shear mixer three 
times to ensure complete dispersion of the MWNTs.  The liquid monomer used was the 
commercially prepared ampule that came with the bone cement powder.  Components 
were manually mixed at room temperature for two minutes in the ratio of 40 g of powder 
to 20 mL of monomer.  Once the cement had reached the doughy phase, it was manually 
pressed into an acrylic mold that produced 6 mm diameter spherical shaped specimens. 
Six specimens were formed for each of the test groups.  They were allowed to cure for 
one hour at room temperature.  The specimens were then weighed individually.  Each 
specimen was immersed in a plastic test tube containing 40 mL of PBS and kept at room 
temperature until the designated sampling times.  At each sampling time, the tubes were 
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slowly shaken three times and then 0.5 mL of the PBS solution was removed and stored 
at -20oC until analysis.  No new PBS was added to the tubes.  Samples were taken at 1, 3, 
6, 24, 48, 96 (4 days), 168 (7 days), 336 (14 days), and 576 (24 days) hours.   
 
The antibiotic concentration in each of the samples was measured using particle-
enhanced turbidimetric inhibition immunoassay (PETINIA).  The antibiotic concentration 
results were multiplied by the total concentration of PBS in the test tube to calculate total 
antibiotic release per bead at each sample interval.  This value was then divided by the 
elution time for the given interval to get an elution rate in µg/hour for each bead.  The 
initial antibiotic elution concentration, total antibiotic elution amount, and elution rate 
from each sample type was compared using a 2-way ANOVA.  Table 3.3 displays the 
average gentamicin elution amounts for the sample beads in each category and the initial 
and final elution rates.  Initial elution rate corresponds to the elution rate after 1 hour and 
the final elution rate corresponds to the elution rate after 24 days. 
 
Table 3.3  Total Elution Amount and Elution Rates for Each Sample Type 
(Average ± Standard Deviation) 
Antibiotic 
Type 
M W N T 
Percentage 
(wt%) 
Total E lution 
Amount (µg) 
Initial E lution 
Rate 
(µg/hr) 
F inal E lution 
Rate 
(µg/hr) 
Powder 0 264.96±20.93 104.0±12.65 0.46±0.04 Liquid 87.0±19.38 62.67±15.73 0.15±0.03 
Powder 0.33 60.0±7.78 36.67±8.91 0.10±0.01 Liquid 187.2±64.52 118.67±38.67 0.33±0.11 
 
Initial elution amount was 50% lower in the samples with liquid antibiotic than powder 
antibiotic.  The addition of MWNTs decreased the initial elution amount by 95% in the 
powder antibiotic samples and increased 14% in the liquid antibiotic samples.  The 
MWNT loaded samples with liquid antibiotic had an increase of 62% elution.  The 
ANOVA results for the initial elution amounts had the forms of antibiotic being 
significant (p=0.03) and the interaction between presence of MWNTs and antibiotic form 




Total elution amount was 100% lower in the samples with liquid antibiotic than powder 
antibiotic.  The addition of MWNTs decreased the final elution amount by 126% in the 
powder antibiotic samples and decreased 34% in the liquid antibiotic samples when 
compared to the Palacos+G.  The MWNT loaded samples with liquid antibiotic had an 
increase of 100% elution from the Palacos and liquid gentamicin samples.  The ANOVA 
results for the total elution amounts had the presence of MWNTs being significant 
(p=0.002) and the interaction between presence of MWNTs and antibiotic form being 
significant (p<<0.001). 
 
Initial elution rate was 50% lower in the samples with liquid antibiotic than powder 
antibiotic.  The addition of MWNTs decreased the initial elution rate by 96% in the 
powder antibiotic samples and increased 13% in the liquid antibiotic samples.  The 
MWNT loaded samples with liquid antibiotic had an increase of 62% elution.  The 
ANOVA results for the initial elution rate had the forms of antibiotic being significant 
(p=0.04) and the interaction between presence of MWNTs and antibiotic form being 
significant (p<<0.001). 
 
Final elution rate was 100% lower in the samples with liquid antibiotic than powder 
antibiotic.  The addition of MWNTs decreased the final elution rate by 126% in the 
powder antibiotic samples and decreased 33% in the liquid antibiotic samples.  The 
MWNT loaded samples with liquid antibiotic had an increase of 73% elution.  The 
ANOVA results for the initial elution rate had the presence of MWNTs being significant 
(p=0.002) and the interaction between presence of MWNTs and antibiotic form being 
significant (p<<0.001). 
 
Figure 3.5 and Figure 3.6 show the total accumulated gentamicin amount per bead and 
the elution rates for each sample type.  Figure 3.5 and Figure 3.6 do not display elution 
amounts or rates for the control samples without antibiotic.  These samples tested using 





F igure 3.5  Total accumulated gentamicin release per bead. 
 
 
F igure 3.6  Elution rate per bead for each sample type. 





















































Section 3.4   Discussion  
 
The pure Palacos+G cement had the largest amount of total gentamicin elution after 24 
days.  If the standard deviation of the Palacos cement with liquid gentamicin and 0.5 wt% 
MWNTs is taken into account, those samples had total elution amounts in the same range 
as the Palacos+G samples.  The elution rates of these two samples were also the most 
similar.   This is an important finding because of the price of liquid gentamicin.  It has a 
much lower cost than the pre-mixed powdered gentamicin.  If bone cement could be 
made with the cheaper liquid antibiotic and a small percentage of MWNTs, the elution of 
antibiotic could be the same as the Palacos+G used presently. 
 
When comparing the samples with the same form of antibiotic and the presence of 
MWNTs, the MWNTs significantly decreased the total elution amount, initial elution 
rate, and final elution rate in the powdered antibiotic case.  While in the liquid antibiotic 
case, the total elution amount, initial elution rate, and final elution rate were increased.  
The increased elution rates initially indicate that more of the antibiotic is being released 
initially.  To have a more prolonged antibiotic release, the elution rates should be 
decreased enough to prolong the release of the antibiotic but not too low in that not 
enough antibiotic is being released.  This may be the reason for the decrease in elution in 
the Palacos+G samples with MWNTs added.  The MWNTs may be decreasing the 
elution rates too much, both initially and over time that not enough antibiotic is getting 
out.  The presence of 0.5wt% MWNTs has already been found to negatively impact 
polymerization.  Complete polymer polymerization does not occur in Palacos samples 
with 0.5 wt% MWNTs.  If the MWNT percentage was decreased to between 0.4-0.5 
wt%, more complete polymerization would occur as a result of increased conversion of 
the monomer to polymer, as well as better elution.  Elution rates and amounts must be 
impacted by the polymerization kinetics of the material.   
 
The study was also completed at room temperature and not a more physiologically 
relevant temperature.  The MWNTs and the antibiotic will not change chemically at 
37oC, but the study should be completed in the most accurate situation for better 
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implantation understanding.  At a higher surrounding temperature, the rate of diffusion of 
the antibiotic out of the bone cement polymer will increase.  It has also been shown that 
polymerization occurs better in the Simplex cement, so an elution study should also be 
run with Simplex cement, MWNTs, and antibiotic to see if the elution properties could be 
improved by just using a different brand of cement.  This brand of cement does have 
initially higher heat flow values during polymerization, even in samples without 
MWNTs, than Palacos cement.  This may indicate that the polymerization reaction can 
negate some of the MWNT influence to more completely polymerize, also allowing for 
further proper elution of the antibiotic out of the system.   
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Chapter 4 - Conclusions and Future Work 
 
Section 4.1 Conclusions 
 
Multiwall carbon nanotubes alter the polymerization kinetics of bone cement.  MWNTs 
increased the time required to completely polymerize the methylmethacrylate monomer 
and decreased the peak exothermic temperature of the bone cement.  The likelihood of 
thermal necrosis is reduced and the mechanical integrity of the cement-bone interface 
will be greatly improved.  The addition of MWNTs to bone cement may also help avoid 
polymerization induced “hot” spots and subsequent hyperthermia-based destruction of 
bone adjacent to the cement mantle.   
 
The strength of bone cement is dependent on polymerization reactions.  If enough 
polymerization reactions do not occur, the material does not harden, and bone cement 
could not be used for orthopaedic surgery.  To have more complete polymerization of the 
bone cement material, the percentage of MWNTs added to the mixture must be 
optimized.  This optimal range should have the increase in mechanical properties due to 
the MWNTs presence make up for the subsequent decrease in polymerization reactions. 
 
The high exothermic temperatures of bone cement polymerization also limit the 
therapeutic potency of the antibiotics used in arthroplasty.  Presently there are less 
expensive antibiotics that would positively prevent orthopaedic infections, but these 
antibiotics denature at temperatures exceeded during polymerization.  Lowering the 
polymerization temperature would increase the choice of antibiotics available to the 
patient and the surgeon.  If the lowered temperature could be achieved without 
diminishing antibiotic potency, it would also positively affect the mechanical integrity of 
the interface and would greatly improve implant longevity.     
 
MWNTs were shown to substantially alter the flow of heat liberated during the 
polymerization of bone cement.  The benefits of this include: 1) new options for use of 
heat-labile antibiotics in TJA, 2) improved antibiotic potency, 3) fewer “hot spots” that 
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can nucleate fatigue cracks, 4) greater biological viability of the bone-bone cement 
interface, and 5) mechanical strengthening of the matrix otherwise weakened by 
antibiotic incorporation.  These benefits support the claim that MWNTs in antibiotic 
laden bone cement can result in enhanced clinical performance of cemented total joint 
implants.   
 
Section 4.2 Future Work 
 
There are many directions for future research involving bone cement augmented with 
multiwall carbon nanotubes.  One important thing to know would be the potency of the 
antibiotic that is released from the augmented bone cement.  This is typically investigated 
using a bioassay.  The results will show whether or not the MWNTs denature or change 
the antibiotic that is released and if the antibiotic has killing power against the bacteria.  
This knowledge is even more important in understanding the potential of the MWNT 
bone cement that the antibiotic elution alone.   
 
There are a variety of other studies typically performed with bone cement including 
fatigue and mechanical testing studies.  It is already known that MWNTs improve the 
mechanical and fatigue properties of bone cement [67], but additional testing on other 
types of cement should be completed.  The different commercial bone cements are 
affected by the MWNTs differently during polymerization.  When testing low viscosity 
cements like Simplex a higher percentage of MWNTs by weight percent is needed to 
alter polymerization.  In higher viscosity cements like Palacos, a lower percentage of 
MWNTs must be used in cement mixtures.  The higher viscosity cement is greater 
affected by the presence of MWNTs and polymerization does not occur at high weight 
percents of MWNTs.  Mechanical testing should include tension and compression testing, 
in either 3 or 4-point bend tests.   
 
Ultrasound has been found to be effective in enhancing the efficacy of antibiotics [88].  It 
has been hypothesized that gentamicin elution could be accelerated with the use of 
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ultrasound.  Another future work study could be to establish the effect of the application 
of low-intensity low-frequency ultrasound on the release of antibiotics from bone cement 
[89].  The hope is to be able to access antibiotics that remain isolated within the bone 
cement and allow them to be released in the surrounding environment.  Application of 
ultrasound during the early postoperative days combined with usage of antibiotic-loaded 
bone cement or systemic antibiotics may contribute to the prevention of implant infection 
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